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ABSTRACT 
Serotonin, 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter with a wide range 
of biological functions. It contributes to the integrity, connectivity and function of the central 
nervous system (CNS). Here in this thesis, we aim to understand molecular and clinical changes 
of the serotonergic systems in Alzheimer’s disease (AD) and related neurodegenerative diseases.  
We studied several aspects of the serotonin system, focusing on the 5-HT1B receptor and 
related molecules. Different models and samples were used to explore this, such as cell lines, 
transgenic animals, human platelets and brain tissues. 
In paper I , we showed that the 5-HT1B receptor, s100A10 (p11), 5-HT, 5-HIAA and 
MAO-A enzyme activity were altered in the neuroblastoma cell line, SH-SY5Y stably transfected 
with the human APP (amyloid precursor protein) gene with the double APP Swedish mutation 
(APPswe). There was a reduction of extracellular 5-HT levels measured in cell medium. 
Moreover, higher 5-HT degradation indices were observed in APPswe cells. A similar pattern of 
proteomic changes was observed in the mice model of AD (Tg2576). Expression of 5-HT1B and 
the serotonin transporter (SERT) are reduced in 2-year-old female mice. These findings suggest 
that the decrease in 5-HT1B in these models might be a compensatory biological mechanism to 
the decreased extracellular 5-HT levels. Together these findings indicate an effect of APPswe 
mutation on the serotonergic system, modulating 5-HT1B and 5-HT metabolites. 
In paper II , we showed that the normal compensatory upregulation of SERT gene 
expression, after the pharmacological blockade of 5-HT1B receptor, is lost in APPswe cells. The 
effect of 5-HT1B modulations on p11 gene expression is complex. Treatment with 5-HT and 5-
HT1B antagonist decreases p11 gene expression in both APPswe cells and control cells. 5-HT 
also increases MAO-A gene expression and the production of 5-HIAA in APPswe cells. In 
addition, our results suggest that the MAPK signaling pathways is affected differently in APPswe 
by 5-HT and 5-HT1B. 
In contrast to control cells, sertraline, a selective serotonin reuptake Inhibitor (SSRI), reduces 
intracellular 5-HT levels and increases indices of 5-HT breakdown (5-HIAA/5-HT ratio) in APPswe 
cells. However, an inhibitory effect of sertraline on MAOA-A activity was also observed in APPswe 
cells. Importantly, no change on extracellular 5-HT or 5-HIAA was seen. We suggest that these 
changes are SERT and MAO-A-independent and could be attributed to biochemical interactions 
between Aβ peptides and 5-HT pathway molecules. 
The results, in this study, illustrate the differences in 5-HT1B-related molecules in AD and 
physiological models when extracellular 5-HT levels and 5-HT1B receptor are modulated. 
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In papers III  and IV  we explored the association of the serotonergic markers to cognitive 
decline, synaptic biomarkers and pathological changes in people with dementia. In paper III , we 
demonstrated that AD patients have lower 5-HT levels in their medium-density platelet fractions 
compared to the group with subjective cognitive impairment (SCI). In the SCI group, those with 
low platelets 5-HT have higher cerebrospinal fluid (CSF) total tau and tau/Aβ42 ratio than those 
with high 5-HT. 
These findings suggest that platelet 5-HT has a potential for being an early proxy for CSF 
biomarkers in AD. 
In paper IV,  our results showed alteration in 5-HT1B levels in the postmortem prefrontal 
cortex (PFC) of people with AD and other dementias, including dementia with Lewy bodies 
(DLB) and Parkinson’s disease dementia (PDD). Higher levels of 5-HT1B were observed in AD 
and DLB groups. Furthermore, 5-HT was reduced in DLB, and 5-HIAA was low in all dementia 
groups. There were significant associations between 5-HT and pathological markers and synaptic 
proteins in DLB. Higher 5-HT1B levels were associated with more rapid cognitive decline in AD, 
PDD and combined dementia group. 
The study indicates an association between prefrontal 5-HT1B levels and cognitive decline in 
dementia. Furthermore, it suggests a potential benefit of 5-HT1B antagonists in enhancing 
memory function in dementia. 
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1 INTRODUCTION 
The human central nervous system (CNS) consists of heterogeneous populations of 
neuronal and non-neuronal cells with complex interactions and evolutions[1]. Synapses connect 
cells and therefore are important for anatomical, structural and functional integrity of CNS. 
Synaptic loss and synaptic protein alterations are implicated in the pathophysiology of 
neurodegenerative diseases[2]. Studying the neuropathology associated synaptic dysfunctions and 
neurotransmitters alterations of dementia are important in understanding the clinical presentation 
or designing a new disease-modifying drug. 
Complex neurochemical signaling, pre and postsynaptic membrane related events constantly 
follow the release of a neurotransmitter. These eventually lead to generation and propagation of 
an action potential, which is the electrical message between neuronal cells at synaptic spaces. 
There are different types of neurotransmitters that are well characterized in terms of structure, 
physiological function and neuroanatomical localization in CNS. Epinephrine, acetylcholine, 
dopamine and serotonin (5-HT) are some examples of these neurotransmitters. 
1.1 Serotonin 
1.1.1 Biological roles of serotonin 
Serotonin or 5-hydroxytryptamine (5-HT) has the old name enterochromaffin substance. The 
word (entero) refers to the gastrointestinal tract (GIT), which is the organ where 5-HT 
expression is most abundant[3]. 5-HT was first proposed as a neurotransmitter after studies 
confirmed the availability of 5-HT is the human brain[4]. 5-HT as a neurotransmitter mediates 
and modulates several physiological functions. 
From a physiological point of view, 5-HT is associated with cognition[5], locomotor 
functions[6], mood stability[7] and the regulation of the sleep/wake cycles[8]. In addition, it is 
important in the regulation of many visceral and vital functions such as gut, bladder, ejaculatory 
and cardiovascular control[9] and the regulation of platelet aggregation in blood hemostasis[10]. 
It is also associated with a wide range of behavioral modalities[11] like impulsive aggression[12], 
suicidal thoughts and events[13] and alcohol or substance addiction[14, 15]. 
Similar to the dopamine system, recent pharmacological and electrophysiological studies 
have demonstrated a role of 5-HT system in the emotional and cognitive mediation of reward 
representation[16]. 
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1.1.2 Neurochemistry of the 5-HT pathway 
5-HT has the “molecular formula C10H12N2O and a molecular weight about 176 gram per 
mole” PubChem Compound Database. The chemical structure of serotonin is shown in Figure 1.1 
 
Figure 1.1 The chemical structure of serotonin. Taken from the open cheminstry database Pubchem, National 
Center for Biotechnology Information. PubChem Compound Database; CID=5202. 
https://pubchem.ncbi.nlm.nih.gov/compound/5202 (accessed June 23, 2016). 
1.1.2.1 Serotonin biosynthesis 
Serotonin (5-hydroxytryptamine, 5-HT) is derived from the essential amino acid L-
Tryptophan after two main enzyme-dependent chemical conversions[17]. 
1. The first main step is achieved by the enzyme tryptophan-5-hydroxylase (Tph), where 
tryptophan is converted to 5-hydroxytryptophan (5-HP). Conversion of L-Tryptophan to 
5-HP is the first and rate-limiting step in 5-HT biosynthesis. However, it includes a 
complex process composed of more than four sub-biochemical reactions. 
2. The second step in 5-HT biosynthesis is a decarboxylation reaction for 5-HP into 5-HT. 
The hydroxylation of L-Tryptophan is regulated by different chemical, physical and 
biological conditions. First, the intracellular levels of L-Tryptophan can modulate Tph 
activity[18]. Increased supply of the substrate L-tryptophan in animal infusion studies lead to 
increase 5-HT synthesis in different body organs including the brain and GIT[18]. Intuitively, 
factors such as concentrations of cofactors and enzyme inhibitors also influence L-Tryptophan 
hydroxylation. 
The extracellular level of 5-HT is an important regulator of 5-HT synthesis process. This 
represents a negative auto-regulation at the presynaptic membrane level, which has a dual effect 
on intracellular 5-HT biosynthesis and extracellular 5-HT release[11]. 5-HT1A and 5-HT1B are 
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particular 5-HT receptor subtypes that are involved in this process. Therefore, molecular and 
physiological factors affecting their expression would indirectly influence 5-HT hemostasis[19]. 
After synthesis, 5-HT is taken into the intracellular vesicles via vesicle monoamine transporters 
(VMATs), which facilitate 5-HT uptake and storage into specialized presynaptic vesicles. 
1.1.2.2 5-HT turnover 
5-HT is degraded to 5-hydroxyindolacetoacetic acid (5-HIAA) by the neuronal monoamine 
oxidase (MAO) enzyme. First discovered by Hare MLC in 1928 and given a name of tyramine 
oxidase, MAOs catalyze the metabolism of a wide range of primary, secondary and tertiary 
amines[20]. In contrast to acetylcholine metabolism, 5-HIAA cannot be recycled into the 5-HT 
pool. 
MAO-based 5-HT metabolism is an oxidation reaction that requires both oxygen and water. 
The localization of MAO in the outer mitochondrial membrane is functionally relevant, since it 
makes the enzyme prone to competition for oxygen by other oxygen consumer enzymes such as 
cytochrome C[21]. Moreover, MAO is not specific to 5-HT and has other monoamine substrates 
such dopamine, noradrenaline (NA) and adrenaline[22]. There are two different MAO isozymes, 
which are encoded by two distinct genes[23], and the enzyme is classified according to the 
substrate specificity and inhibitors sensitivity into isozyme A and B[21]. Beside the similarity in 
functions and the types of substrates, MAO-A and MAO-B are structurally identical in about 
70% of the amino acid sequence[24]. 
Although MAO-A is relatively more specific to 5-HT and the main enzyme in 5-HT 
metabolism, 5-HT is also metabolized by MAO-B in brain and the GIT. Different biochemical 
factors determine the isozyme-switch between MAO-A/MAO-B in 5-HT metabolism. In 
addition to the type of biological tissue, the preference of the isozyme subtype in 5-HT 
metabolism depends on the availability of 5-HT. In brain, 5-HT is exclusively metabolized by 
MAO-A in conditions of low concentrations. Even in high 5-HT concentrations, MAO-B 
contributes by only 10% to 5-HT metabolism[21]. The expression of MAO-A and MAO-B has 
significant variations across different types of tissues. This variability in expression reflects the 
functional variability in serotonin metabolism and transmission depending on body systems[25]. 
Platelets are example of tissue that expresses only MAO-B. 
MAO is subjected to a group of endogenous inhibitors that modulate the enzyme 
kinetics[26, 27]. For example, the small molecule neurocatin was shown to maintain 5-HT levels 
and inhibit the catabolism of 5-HT by inhibiting MAO[28, 29]. Moreover, two distinct 
isoquinolinium molecules show a significant inhibitory effect on MAO-A[30]. Similarly, smoking 
was also reported as inhibitor for both MAO-B[31] and MAO-A[32]. Inhibition of MAO is an 
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old and well-known strategy in the treatment of depression. The monoamine oxidase inhibitors 
(MAOIs) are classical class of antidepressants. Moreover, the efficacy of MAOIs in posttraumatic 
stress disorder (PTSD) indicates that stressful condition might contribute to the modulation of 
MAO[24, 33]. 
However the clinical application of MAOIs is limited by, among others, the interactions with 
milk products, smoking and alcohol [34]. A pattern of bidirectional interactions between MAO 
subtypes and alcohol was observed from previous reports. Alcohol is associated with modulation 
of MAO activity. On other hand, certain MAO-A gene mutations are associated with alcohol 
addictions[35]. Moreover, lower MAO-B activity is demonstrated in Alcoholism[36]. 
5-HIAA is an indicator of 5-HT turnover or serotonergic neuronal activity, and is considered 
as a valuable biomarker in 5-HT over-production disorders. For example, in case of 5-HT-
secreting tumors such as carcinoid tumors typical clinical symptoms, radiological evidence of 
gastrointestinal mass and increased levels of 5-HIAA in the urine are the diagnostic triad of the 
tumor diagnosis[37]. Since the balance between 5-HT biosynthesis and degradation is an 
important measure in 5-HT hemostasis, 5-HIAA/5-HT ratio could also be a better reflection of 
the 5-HT turnover than levels of 5-HIAA alone[21]. The superiority of 5-HIAA/5-HT ratio 
comes from the fact that it takes into consideration the amount of 5-HT available in a particular 
system. 
1.1.3 Neuroanatomy of serotonin 
Anatomical considerations are essential in understanding the function of 5-HT system in 
both physiological and pathological states. Of note, the serotonergic system is not an isolated 
entity and has dense interactions with other non-serotonergic systems. 
1.1.3.1 Serotonergic neuron in CNS 
The presence of the serotonergic cell bodies in the brain stem was proposed by Dahlström 
and Fuxe in 1965[38]. With serotonergic neurons originating in the raphe nucleus (RN) in the 
brainstem, the serotonergic system represents the most abundant monoamine system in the 
CNS[39]. In a non-overlapping manner, serotonergic fibers form wide projections to different 
brain regions and the spinal cord[40, 41]. There are ascending serotonergic projections to septa, 
thalamus, hypothalamus, putamen, hippocampus and different cortical areas[41, 42]. These 
ascending projections are separated according to the origin from the RN. The median raphe 
nucleus projects to the forebrain and the medial part of septa, while the dorsal raphe nucleus 
innervates the frontal cortex, hippocampus and the striatum[42]. 
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1.1.3.2 5-HT1B receptor mapping in CNS 
Currently, 14 subtypes of 5-HT receptors are characterized in the human brain[43]. Each 5-
HT receptor has a specific expression pattern in CNS. This multiplicity adds to the functional, 
physiological and pharmacological complexity of 5-HT system. 
5-HT1A and 5-HT1B receptors are expressed in both pre and postsynaptic neurons, with a 
predilection to the presynaptic expression[44-47]. The 5-HT1B receptor is localized to both cell 
bodies and axon terminals. The receptor protein is trafficked from cell bodies through the axons 
to neuronal terminals[48]. In 5-HT1B knockout (5-HT1BKO) mice, overexpression of 5-HT1B 
in the striatum leads to specific transport to the globus pallidus (GP) and the substantia nigra 
(SN)[44, 49]. In agreement with these findings, binding and immunohistochemistry studies have 
showed that 5-HT1B has a dense distribution in the basal ganglia nuclei such as GP, SN and the 
hippocampal area subiculum[44, 50-53]. Lower 5-HT1B receptor densities were observed in the 
hypothalamus, striatum, hippocampus, spinal cord and amygdala[44, 53-55]. However, there is a 
discrepancy between the receptor protein and messenger RNA (mRNA) distributions evaluated 
with In Situ Hybridization histochemistry (ISHH)[44]. 
In contrary to the 5-HT1B receptor protein expression, mRNA binding studies showed no 
binding in SN and GP[45], and low levels in RN and striatum[56]. 5-HT1B has 5 major locations 
in terms of availability according to the majority of gene expression reports[44]: 
• Striatonigral pathway. 
• Raphe nucleus. 
•  Other basal ganglia nuclei (putamen, caudate and globus pallidus). 
• Cerebellum. 
• Hippocampus: pyramidal neurons of region I of hippocampus proper (CA1)[57]. 
1.1.3.3 Serotonin transporter (SERT, SLC6A4) 
The function of 5-HT transporter (SERT) is to reuptake serotonin from the synapses or 
extracellular space to the intracellular space. It represents the high affinity return system of 5-HT, 
which is a sodium (Na) and chloride (Cl) dependent mechanism. Using 5-HT1BKO animals, it 
was shown that the mechanism by which SERT regulates 5-HT transmission is complex and 
includes collateral signaling with other molecules such as 5-HT1B (Figure 1.2). In addition, 5-
HT1B antagonism, using the 5-HT1B selective antagonist SB224289, decreases SERT 
function[58]. 
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Figure 1.2 Role of 5-HT1B receptor in SERT function and 5-HT uptake. Lower levels of 5-HT 
reuptake are observed in genetic deletion of 5-HT1B (Hagan et al, 2012), permission was taken from the 
publisher John Wiley and Sons. 
 
SERT is expressed in brain, pulmonary vasculature, placenta and platelets. However, studies 
have shown that the brain SERT is the main site of action of antidepressants[59, 60]. 
Functionally, SERT has also a neurodevelopmental role in adjustment of the cortical sensory 
mapping during the critical period of brain development[61]. The distribution of SERT is also 
relevant to the neuropathology of affective disorders. Lower densities of SERT were reported in 
patients diagnosed with depression. Similarly, SERT densities are lower in winter compared to 
summer in healthy subjects, which suggests a role for SERT distribution in affective seasonal 
mood disorders[62]. 
Following the 5-HT neuronal projection, SERT protein is widely expressed in the human 
brain. It represents a marker for 5-HT projection mapping. All brain areas express more or less 
SERT, with the cerebellum being the lowest SERT expression brain area[63]. Binding studies 
have shown that the distribution of SERT in the raphe nucleus is similar to that of serotonergic 
neurons[64]. Relevant to the memory and memory processing, the density of SERT is high in the 
temporal entorhinal cortex[65]. In addition, SERT is abundant in limbic system and the levels 
here correlate to the 5-HT neuronal innervation[65, 66]. Intuitively, levels of SERT expression 
contribute to the binding of selective serotonin reuptake inhibitors (SSRIs) in these memory-
related brain areas. Furthermore, brain areas that have high density of SERT protein like 
hypothalamus and forebrain would have higher receptor occupancy[66]. 
1.1.4 Pathophysiological implications of 5-HT system 
The serotonergic system is linked to many physiological functions. It significantly influences 
the function of different body systems, like the musculoskeletal, CNS, and cardiovascular system. 
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It has also complex interactions with other neurotransmitters and intracellular molecules. 5-HT 
receptors belong to seven different families (5-HT1 to 5-HT7) and subdivided into further 14 
different subtypes[67]. 5-HT3 is a ligand gated ion channel receptor; while other 5-HT receptors 
exert their downstream signaling through a G-protein coupled pathway[68]. 
1.1.4.1 Serotonin and cognition 
5-HT plays an important role in the cognitive function. Serotonergic system modulators are 
essential in the treatment of many neuropsychiatric disorders[69, 70]. High-order brain functions, 
mapped to the prefrontal cortex (PFC) such as learning, working memory and cognitive flexibility 
are classified as executive brain functions[71]. The dense 5-HT innervation and expression of 5-
HT receptor subtypes in PFC, together with the anatomical and functional connections between 
PFC and raphe nucleus indicate the impact of 5-HT in memory[71]. 
Beside cognitive flexibility, 5-HT contributes to the function of short-term memory (STM), 
and long-term memory (LTM)[41]. Cognitive decline is an age-related phenomenon. Impairments 
in memory and learning are associated with aging[72], and with both cholinergic and serotonergic 
disturbances[73]. 
Genomic analysis of hippocampal 5-HT receptor subtypes, using DNA microarray 
technique, has shown differential gene expression changes. This was dependent on the type of 
behavioral paradigm and time points during task performance in two different behavioral tasks, 
the water maze learning and the passive avoidance conditioning. This experiment illustrates 
modulations of 5-HT in memory and learning[74]. 
Different subtypes of receptors, according to specific localization in the brain, have different 
contribution to age-related memory decline. 5-HT1A is associated with memory for object 
location in human[75]. Learning difficulties, such as working memory impairment and task 
difficulty-dependent delay, were reported in 5-HT1BKO mice[76]. 
 Disturbances in serotonin system can lead to disturbances in cognitive flexibility and 
difficulty to adapt to changes in task environment[77]. For example, animal models with low 
brain 5-HT levels, produced by acute tryptophan depletion (ATD) or destruction of the 
ascending serotonergic projections, have low cognitive flexibility indices and impulse control[78]. 
ATD, as a temporary method to reduce brain 5-HT concentration, affects not only cognitive 
function but also emotion processing. It was shown that ATD affect BOLD response, which is a 
measure of emotion processing, in brain areas relevant to depression like the amygdala[79]. In 
addition, 5-HT can influence cognitive functions in both direct and indirect ways[41]. 5-HT can 
affect the memory indirectly by modulating other neurotransmitters like dopamine, acetylcholine 
and GABA. 
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5-HT depletion in the prefrontal cortex (PFC) leads to cognitive inflexibility[80]. This effect 
is seen in dementia, schizophrenia[81] and obsessive-compulsive disorders (OCD)[82]. However, 
involvement of 5-HT in OCD pathophysiology is also related to the implication of 5-HT in 
controlling impulsive behavior[83]. These findings are consistent with the data that shows 
positive effects of serotonin-enhancing drugs, such as tricyclic antidepressant (TCA) and SSRIs, 
in treating OCD symptoms[80]. Furthermore, brain prefrontal 5-HT dysfunction is specifically 
associated to preservative symptoms[80]. However, these clinical symptoms are not necessarily 
attributed to PFC-5-HT dysregulation alone. 
Other pathophysiological factors, such structural and biochemical changes, might play part 
as well. Structural brain changes, inflammatory process and other neurotransmitters disturbances 
are involved in pathophysiology and symptomatology of these disorders that affect the PFC[84]. 
5-HT was shown to modulate neuronal activity in PFC in both in vitro and in vivo studies. In 
contrast to 5-HT2A, which has a cortical excitatory effect[85], activation of 5-HT1A leads to 
inhibitory effect on pyramidal neurons due to hyperpolarization of the neurons[86]. In vivo studies 
also have demonstrated the effect of 5-HT on modulating the PFC neuronal activity. Yet, it is 
difficult to isolate individual effect of 5-HT on 5-HT subtypes of receptor since the in vivo effect 
refers to activation of a group of receptors. Like the in vitro models, 5-HT1A is inhibitory to PFC 
pyramidal neurons, while 5-HT2A is a excitatory receptor in vivo[87]. The detailed mechanism is 
still unknown despite the large number of electrophysiological reports studying the 5-HT action 
on the PFC pyramidal network in different behavioral states[71, 88-90]. 
The complex relationship between 5-HT system and cognitive functions is attributed to 
different aspects. Firstly, the effect of 5-HT is brought by activation of both pre- and 
postsynaptic neurons, which leads to a complex and different signaling depending on the type of 
receptor being activated[73]. Secondly, there is a well-documented interaction between 5-HT 
receptors and other neurotransmitters. Finally, results extracted from receptor ligands are 
inconsistent and dependent on behavioral state. 
1.1.4.2 Serotonin and the mood 
5-HT system is central in the pathogenesis and the therapeutics of depression[91]. The 
monoamine hypothesis of depression presumes an imbalance of 5-HT transmission in the 
synaptic space leading to the causation of clinical syndrome of depression[92]. The concept of 
treating depression or enhancing the availability of 5-HT in brain has moved strategically between 
different developmental milestones. It started in the 1960 by blocking MAO enzyme to decrease 
5-HT turnover, and moved to systematically manipulate the intracellular monoamine 
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signaling[93]. The desired outcomes in the strategy of augmenting extracellular 5-HT 
concentrations are enhancement of neuronal plasticity and synaptic transmission. 
There are additional factors that influence the clinical presentation and severity of depression 
such as dysfunctional hippocampal neurogenesis[94], inflammation[95] and neuroendocrine 
stress[96]. Modulations of 5-HT1B and 5-HT1A activities are addressed in the therapeutic 
strategies for major depressive disorders. Moreover, the activation of 5-HT1B and 5-HT1A 
during the treatment with SSRIs represents a major challenge for conventional antidepressant 
pharmaceuticals[97]. 
1.1.5 Physiological Aspects of selected 5-HT Receptor subtypes 
1.1.5.1 5-HT1A 
The very first successful attempt to clone a 5-HT receptor was reported in 1988 by Fargin et 
al, using a β-adrenergic receptor probe after being targeted by preceding molecular attempts to 
characterize 5-HT1A[98]. It has a dense expression in the RN, which is predominately auto-
regulatory presynaptic type that negatively regulate the 5-HT release and extracellular 5-HT 
levels[99]. In contrary, the postsynaptic receptor is expressed in the limbic system, neocortex, 
hypothalamus[100] and cortical brain areas[101]. 
5-HT1A has an additional regulatory role on dopaminergic and cholinergic transmission[73]. 
The co-localization and co-expression of 5-HT1A and cholinergic markers in cholinergic neurons 
have been reported[102]. The functional consequences for this co-expression are the integrated 
role of cholinergic and serotonergic system in learning and memory. The associated deficit of 5-
HT and acetylcholine in age-related memory deficit and brain neurodegenerative disorders are 
reported[102]. A dense expression of 5-HT1A is also seen in the hippocampus. Removal of 5-
HT1A in 5-HT1A knockout mice impairs the hippocampal-dependent learning. This indicates 
the important role of the 5-HT1A in hippocampal function[103]. 
 The therapeutic potential of targeting 5-HT1A has been widely tried in different 
neurocognitive, mood and behavioral disorders such as anxiety, depression, schizophrenia and 
Parkinson’s disease[104]. Although studies from 5-HTA full or partial agonists have inconsistent 
results regarding the outcomes in memory[105], some 5-HT1A antagonists have shown potential 
benefits in treating cognitive dysfunction[106]. The old generation of selective 5-HT1A agonist, 
S20244, produces anxiolytic effect on mice[107]. Similar effect is also noted in the partial 5-
HT1A-agonist buspirone. However, buspirone is not selective to 5-HT1A since it alters 
GABAergic and monoaminergic pathways[108]. Moreover, the non-specific 5-HT1A agonists 
LY228729 and 8-OH DPAT have more predilection to 5-HT1A than 5-HT1B and 5-HT7 
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respectively[109]. In 2013, vortioxetine, a non-selective 5-HT1A agonist and SSRI, was approved 
for the treatment of major depressive disorders (MDD)[110]. In addition, 5-HT1A agonists are 
also shown to be beneficial in the treatment of neuroleptics-induced extrapyramidal side 
effects[111]. 
One of the challenges with SSRIs treatment is the activation of 5-HT1A that would 
consequently lead to a negative feedback inhibition on terminal 5-HT release and delayed SSRIs 
effects. SSRI-induced 5-HT1A activation was shown to be corrected by pindolol, a mixed 5-
HT1A selective antagonist and β-adrenoreceptor antagonist[112]. The delayed effect of SSRIs is 
partly attributed to the time needed for desensitization of 5-HT1A receptor. That is why the 5-
HT1A receptor antagonists were proposed as adjuvant therapy to the SSRIs to potentiate the 
increase in extracellular 5-HT and accelerate the onset of SSRIs effect[113]. Among the candidate 
drugs were the selective 5-HT1A antagonists WAY100635 and NAD-92. These drugs have the 
advantages of their high potency, ability in achieving high brain concentrations and improving 
cholinergic-related cognitive dysfunctions in AD[114]. Consistent with this notion, compensation 
of the cholinergic activity involved in working memory by the blockade of 5-HT1A using the 
antagonist NAN-190 was shown in rat[115]. 
5-HT1A is proposed as a molecular marker for cognitive function and a target for treatment 
in cognitive decline[116]. Moreover, interference with the 5-HT1A-gene expression through 
siRNA-mediated suppression of 5-HT1A produced beneficial outcomes in depression[97]. This 
leads to increased extracellular 5-HT levels, augmented SSRIs effect and showed promising 
results in behavioral studies in mice[97]. These results are in agreement with other reports that 
indicate the benefit of 5-HT1A antagonists in depression. 5-HT1A antagonists modulate 
complexes formation between 5-HT1A and other intracellular molecules. For instance, 5-HT1A 
forms complexes with brain derived fibroblast growth factor receptor-1 (FGFR-1), which 
enhance hippocampal neuroplasticity[117]. Interestingly, the antidepressant effect of SSRIs is 
partially mediated through this complex due to alteration of hippocampal plasticity and 5-HT 
system in the limbic system[118]. Such findings suggest an indirect role of 5-HT1A in regulation 
of SERT function and SSRIs effects. 
The effect of 5-HT1A antagonist is derived from its implication in the pathophysiology of 
depression[119]. Higher density and activity of presynaptic 5-HT1A predispose to affective 
disorders, severe depressive episodes and poor response to antidepressant[120]. Consistent with 
this, it was shown that the activation of the presynaptic receptor decreases 5-HT release[121]. In 
addition, 5-HT1A agonist might facilitate dopamine release ventral tegmental area[122]. This 
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reflects the significance of 5-HT1A to neuroleptics used in the treatment of psychotic 
disorders[123]. 
1.1.5.2 5-HT1B 
This receptor was classified as one entity together with 5-HT1D because of their high 
homology, pharmacological similarities and the fact that both subtypes of receptors inhibit 
adenylate cyclase[124]. However, this relationship was latterly elaborated in terms of phylogenic 
basis. It was shown that rat 5-HT1B receptor is the homolog and species variant to the human 5-
HT1D receptor[125]. 
There are few differences between human 5-HT1D and rat 5-HT1B in terms of 
pharmacological characterization[44]. For example, the rat receptor has more binding affinity to 
certain ligands such as the β-adrenergic antagonist propranolol. This is attributed to a difference 
in a single amine acid (threonine in position 335 in human 5-HT1D and asparagine in the same 
position in rodent 5-HT1B) in the receptor putative transmembrane domain[44, 126]. 
5-HT1B, similar to many of 5-HT subtypes including 5-HT1A, belongs to Gαi-coupled 
receptors. These receptors exert their downstream signal transduction through inhibition of 
adenylate cyclase and subsequently lead to reduction of the second messenger cyclic adenosine 
monophosphate (cAMP)[127, 128]. This canonical signaling pathway is named the signaling 
pathway. Here, signals for complex and diverge biochemical and physiological effects are 
transduced[128]. However, a separate cAMP-independent intracellular signaling was also 
characterized for the down stream effect of 5-HT1B. Reports have demonstrated the coupling of 
5-HT1B to the mitogen-activated protein kinase (MAPK) Erk-2 and the related kinase p70 S6 in 
non-sequential signal transduction pathways[129]. 
5-HT1B has both presynaptic and postsynaptic distributions. The cellular localization of 5-
HT1B is variable depending on the tissue type[44]. In neuronal cells, axonal expression is the 
predominant and 5-HT1B transported to axon terminal from cell bodies[45, 49, 130]. The 
variability of 5-HT1B expression across different brain areas was reported by binding, 
immunohistochemistry and in situ hybridization studies of 5-HT1B mRNA[44, 56]. 
Higher levels of 5-HT1B were found in the basal ganglia nuclei globus pallidus (GB) and 
substantia nigra (SN), with the preferential transport of the receptor’s protein along the 
serotonergic projections to these nuclei[44]. Lower receptor protein levels were detected in the 
cerebral cortex and hippocampus[44, 50, 54]. This was confirmed by in situ hybridization studies, 
using cDNA probe encoding 5-HT1B. This has shown that 5-HT1B mRNA is expressed in the 
median and lateral raphe nucleus and CA1 area of the hippocampus[57]. 
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Similar to the 5-HT1A, the presynaptic 5-HT1B is an auto-regulatory receptor that control 
5-HT release through a negative feedback mechanism[16, 131]. The increased activity of these 
receptors lead to inhibition of 5-HT release, and thus takes part in the regulation of the 
extracellular 5-HT levels together with SERT[58]. However, the caudate nucleus, where 5-HT1B 
increase 5-HT release, is the only exception for this inhibitory effect of 5-HT1B on 5-HT[132]. 
This indicates that the mechanism of 5-HT1B in modulating extracellular 5-HT is more complex 
in basal ganglia’s circuits[132]. 
The interaction between the extracellular 5-HT and the activity or expression of both 5-
HT1A and 5-HT1B are relevant to depression[133]. Although the desensitization of these 
receptors is required for higher synaptic 5-HT levels and thus antidepressant effect, 5-HT1B and 
5-HT1A are mandatory for a long-term antidepressant effect[133]. 5-HT1BKO mice have 
decreased sensitivity of 5-HT1A to the SSRIs and the animal fail to modify stress adaption[133]. 
In addition, 5-HT1B also modulates SERT function in terms of 5-HT reuptake from the 
extracellular compartment under physiological conditions, which is necessary for the SERT-
mediated SSRI function[58]. These findings suggest a functional connectivity between 5-HT1B, 
5-HT1A and SERT. However, the exact mechanisms by which 5-HT1B modulate 5-HT1A and 
SERT functions, or vice versa, are not yet well understood. Beside the negative autoregulatory 
mechanism of 5-HT transmission and synthesis, 5-HT1B influences the transmission of other 
transmitters and thus acts as both autoreceptor and heteroreceptor[44]. For example, 5-HT1B is 
inhibitory to acetylcholine release in hippocampus and interference with 5-HT1B modulates 
acetylcholine levels in the hippocampus[134]. 
5-HT1B has significant implication on behavior as shown in animal studies[16]. Inhibition of 
5-HT1A and 5-HT1B in the dorsal raphe nucleus facilitate rewarding and increasing the receptors 
activities, by selective 5-HT1A and 5-HT1B agonists, facilitates avoidance or averseness[16]. 
Studying the genetic variation of the single exon 5-HT1B gene has shown significant 
implication on cognitive domains such as motivation and memory. Additionally, 5-HT1B genetic 
polymorphisms associates with neuropsychiatric disorders and symptoms[135]. Some mutations 
of 5-HT1B gene, affecting the binding domain or the regulatory region of 5-HT1B, could 
influence the efficacy of certain antidepressant and antipsychotic medications[135, 136]. 
1.1.5.2.1 5-HT1B and memory  
5-HT1B is relevant to memory. Activation of 5-HT1B in hippocampus impairs both 
working and reference memories and affects the spatial memory tasks in rat[135, 137]. Similarly, 
the 5-HT1BKO mice have selective facilitation of task difficulties related to spatial memory[76]. 
5-HT1BKO mice showed impairment in task related to intermediate memory and the delay-
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dependent working memory[138]. However, 5-HT1BKO animals perform better in tasks that 
require aspect of memory flexibility[135]. Additionally, due to the resultant negative tone on 
acetylcholine, 5-HT1BKO animals lack the visual inhibition that could explain the inattentive 
behavior observed in them[135]. This indicates the relevance of this receptor in attention deficit 
hyperactivity disorder (ADHD). These reports, together, reflect the complexity of the 5-HT1B 
contributions to memory function particularly when situation factor or cognitive demand is 
required[76]. It might also indicate the variation in 5-HT1B function depending on the 5-HT1B 
localization in different brain networks and areas[135]. 
1.1.5.2.2 5-HT1B and anxiety 
 Reduction of fear or stress is achieved by increasing 5-HT1B functions through either 
overexpression of the 5-HT1B or the use of a selective 5-HT1B agonist[16, 139]. However, in a 
different report 5-HT1B stimulation exacerbates anxiety in rats. This effect is reversed by the 
concomitant administration of a selective 5-HT1B antagonist, while no isolated anxiolytic effect 
of the antagonist alone was noted[140]. Except for the 5-HT1B antagonist propranolol, the 
results from other 5-HT1B antagonists on anxiety state showed contradicted results. Previous 
reports did not demonstrate correlation between the anxiolytic effect and changes in the levels of 
5-HT after 5-HT1B modulations[41, 141]. 
The association of 5-HT1B and anxiety could be an indirect effect through influence of 5-
HT1B on neurotransmitters other than 5-HT such as acetylcholine and GABA[44, 142]. Because 
of the inhibitory tone to acetylcholine release in cholinergic neurons in the dorsal hippocampus 
and acetylcholine activity has an anxiolytic effect[143], it is suggested that heterogeneous 5-HT1B 
receptors mediate the anxiety behavior through the inhibition of acetylcholine[44]. Similar to that 
with memory, the association with anxiety and fear is dependent on the anatomical localization of 
the 5-HT1B in the brain. Diffuse overexpression of 5-HT1B in brain reduced anxiety in mice, 
while selective overexpression of the receptor in the dorsal raphe nucleus (DRN)-amygdala 
circuit had increased anxiety in wild type but not 5-HT1BKO mice[144]. This suggests that the 
control of anxiety response through 5-HT1B is circuit-specific and partially controlled by the 
DRN and the upstream projections to the hippocampus[44]. However, no change in 5-HT1B 
gene expression was observed after subjecting animal to sudden or prolonged stress stimuli[145]. 
1.1.5.2.3 5-HT1B and depression 
5-HT1B dysfunction is linked to the pathophysiology of depression[44]. In addition, 5-
HT1B genetic polymorphisms, particularly G861C and C129T, are related to the development of 
mood disorder[146, 147] and response to antidepressant[148]. Electrophysiological studies in rats 
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revealed that 5-HT1B stimulates activating signals that contribute to the pathophysiology of 
depression[149]. Although these presynaptic excitatory signals are not specific to 5-HT1B, 5-
HT1B has significant interaction with other molecules that influence these signals such as 
glutamate[149-151]. Moreover, the expressions of 5-HT1B and its adaptor protein p11 are 
reduced in human brain and animal models of depression[152, 153]. 
The use of antidepressant decreases the gene expression of the presynaptic 5-HT1B in DRN 
in a reversible pattern[154]. This would reflect a particular phenomenon that an antidepressant 
has to overcome the negative tone of 5-HT1B on 5-HT transmission in order to produce a 
clinical effect. In other words, desensitization and inhibition of 5-HT1B function is mandatory 
for an antidepressant action[155]. In agreement with this, PET studies have showed that the 5-
HT1B binding in brain is reduced in the dorsal brain stem (DBS) after effective treatment of 
MDD[156]. However, this requires a relatively long time to occur and could probably explain the 
delayed-onset of improvement in depressive symptoms following administration of 
antidepressant[157]. However, an antidepressant-like effect was observed for the 5-HT1B agonist 
(CP94253) in mice in the forced swimming test and the mechanism is postulated to be through 
activation of postsynaptic 5-HT1B together with modulation of dopamine and adrenaline[157, 
158]. Of note, the data from studies investigating the role of pharmacological modulations of 5-
HT1B and its association with antidepressants effect are not showing conclusive results[157]. 
Such data would depend on the duration of 5-HT1B modulations and presence of 
antidepressant-like effect[159]. 
1.1.5.2.4 5-HT1B and aggression 
5-HT deficiency is postulated as a contributing mechanism for aggression and suicidal 
events[44, 160, 161]. Therefore, increasing the level of 5-HT in brain through pharmacological 
modulation of 5-HT1A and 5-HT1B was a tempting strategy to control aggressive life-
threatening events and symptoms[162]. However, this is challenged by the fact that 5-HT1B has 
complex association with different behavioral neuropsychiatric disorders[135]. Aggressive 
behavior was observed in 5-HT1BKO mice[163] and after the administration of the 5-HT1B 
antagonist, while it could be reduced by using the selective 5-HT1B agonist[162]. Similar to 
memory and anxiety (see section 1.1.5.2.1 and 1.1.5.2.2), the anatomical localization of 5-HT1B 
may influence aggression. 5-HT1B receptor expressed in the non-serotonergic neuron in the 
frontal cortex during development were shown to be associated with the impulsivity[164]. 
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1.1.5.2.5 5-HT1B and substance abuse 
Serotonin system in general and particularly 5-HT1B are implicated in alcohol dependence 
and related alcohol uptake disturbances[165-167]. The effect of 5-HT1B autoreceptor on alcohol 
intake and 5-HT1B heteroreceptors through their role in pathophysiology of impulsivity and 
aggression were reported[164]. Particular 5-HT1B ligands, depending on 5-HT1B subtype and 
being auto or hetero-receptor, have a potential in both modulating 5-HT1B function and altering 
alcohol intake behavior[167]. Reports discussing the association between 5-HT1B and alcohol 
intake are not conclusive. However, early reports suggest increased alcohol intake in 5-HT1B KO 
mice together with lower densities of 5-HT1B in rat with higher alcohol intake indices[167-169]. 
The discrepancy from the data derived from animal models of 5-HT1B is attributed to age and 
sex of animals[170]. Interestingly, stimulation of 5-HT1B by the selective agonist CP94253 
reduced the aggressive behavior associated with alcohol abuse[171]. 
The expression and activity of 5-HT1B in different brain circuits are relevant to cocaine 
abuse. 5-HT1B and p11 reduction can be a risk factor or a consequence of cocaine intake. Their 
downregulation in certain brain area might predispose to higher susceptibilities to cocaine 
intake[172, 173]. Conversely, some reports suggested that the upregulation of 5-HT1B gene 
expression, in nucleus accumbens and dorsal striatum, could be a molecular marker for failure to 
keep cocaine abstinence after long-term withdrawal[174]. 
1.1.5.2.6 5-HT1B and migraine 
Serotonergic disturbances are also implicated in the pathogenesis of migraine[44]. The 
extracellular levels of 5-HT metabolites are generally reduced in patients with migraine[175]. 
Increased activity of 5-HT1B in vascular system of territories supplied by the trigeminal artery is 
linked to vasodilation, increased blood supply and aggravation of symptoms seen in typical 
attacks of migraine[176]. 
Similar to 5-HT1D, 5-HT1F and 5-HT7, 5-HT1B receptor agonists are clinically preferable 
to the conventional analgesics and ergotamine. This is attributed to the neurovascular distribution 
in the head, higher safety index, well-documented pharmacodynamics mechanisms and their 
efficacy in alleviating the symptoms of migraine[177]. 
1.1.5.2.7 5-HT1B-adaptor protein p11 
S100A (p11) acts as an adaptor protein for 5-HT1B receptor[153]. It belongs to a family of 
calcium-binding proteins that adjusts the target protein response to levels of intracellular calcium 
and work to place protein to their corresponding functional membranous localization[178]. Also, 
it increases 5-HT1B membranous expression, which has positive influence on the mood and 
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facilitates the antidepressant action[153]. In addition, neuronal plasticity resultant from the 
positive effect brain-derived neurotrophic factor (BDNF) on spine and dendritic growth are 
mediated by p11 in hippocampal cells[179]. They have shown, in different models, how p11 
through 5-HT levels and BDNF facilitates an antidepressant action. In addition, removal of the 
p11 from the system produces a depression-like behavior in animal[153]. p11 is not an exclusive 
functional and structural protein for 5-HT1B. There is a similar association between p11 and 5-
HT4[180]. As seen in case of 5-HT1B, p11 enhances membranous expression of 5-HT4 and 
promotes an antidepressant effect through this 5-HT receptor[180]. Moreover, the biological 
effect of p11 through 5-HT1B is not restricted to depression. It contributes to different 
physiological and pathological aspects of 5-HT1B function such as memory, anxiety, locomotor 
function, aggression and substance abuse[181].   
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1.2 Alzheimer’s disease 
This disease represents the most prevalent type of dementia and is considered as a major 
global health problem[182]. According to the Delphi consensus on dementia, there are currently 
more than 20 million people are affected by AD worldwide and estimated to increase to more 
than 80 million after 30 years[182, 183]. The disease has a significant impact on the quality of life 
of the affected patients, contributes to the increase of mortality rates in elderly age groups and 
represents a high burden on health care systems and caregivers’ quality of life[184]. 
1.2.1 Epidemiology 
AD is an age-associated disease and the incidence therefore depends on how old or young 
the studied population is. Other factors such as the adopted diagnostic protocol, the incidence of 
vascular risk factors and life style play a role in the variation of epidemiological measures across 
ethnic and geographical group[185]. 
There is uncertainty regarding the worldwide incidence of AD. Epidemiological studies with 
acceptable methodological quality in Alzheimer’s disease research are conducted in restricted 
areas such as Japan, USA, Europe, Australia and Canada[183]. However, the global distribution 
of the diseases and the rise of the disease in developing countries necessitate an effective and 
well-integrated international program for epidemiological data from all over the world[183]. In 
the developed countries like USA, AD represent the 5th common cause of death in the age group 
over 65 years following heart attacks, cerebrovascular accidents, cancer and chronic obstructive 
pulmonary diseases[186]. The financial burden includes cost of treatment in health care 
institutions and the working hours of the caregivers, which is an estimated loss of more than 250 
billion dollars[184]. More than 24 million were affected by AD and the number is expected to 
reach more than 80 millions after 25 years[182]. 
1.2.2 Risk factors 
Different genetic, biological, environmental and behavioral factors have been proposed as 
risk factors or preventive factors. Beside age and genetic factors, AD is associated with wide 
range of vascular risk factors such as hyperlipidemia, diabetes mellitus, hypertension, unhealthy 
life style and obesity[187]. However, combined epidemiological and pathological studies have not 
shown an association between these vascular risk factors and the severity of AD[188]. Studies 
have shown that modification of risk factor could affect the onset and progression of dementia. 
This is dependent not only on the amount or duration of the exposure to a particular risk 
factor[189], but also to the presence or absence of certain genetic risk factors such as ApoE ε4 
allele[190]. 
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Table 1.1 shows risk and protective factors in AD[191]. 
Table 1.1 Risk and protective factors in AD 
Risk factors Protective factors 
Age Genetic 
Genetic 
Familial aggregation 
Different genes (e.g. APP, ApoE ε2) have been 
proposed (www.alzgene.org) 
ApoE ε4 Psychosocial factors 
Different genes (e.g. CR1, PICALM, CLU, 
TREM2, TOMM40) have been proposed 
(www.alzgene.org) 
High levels of education and SES 
High level of complexity of work 
Vascular and metabolic Rich social network and social engagement 
Cerebrovascular lesions Mentally stimulating activity 
Cardiovascular diseases Lifestyle 
Diabetes mellitus and pre-diabetes Physical activity 
Midlife positive association but late-life negative association Moderate alcohol intake 
Hypertension Diet 
High BMI (overweight and obesity) Mediterranean diet 
High serum cholesterol PUFAs and fish-related fats 
Lifestyle Vitamins B6 and B12, folate 
Smoking Antioxidant vitamins (A, C and E) 
High alcohol intake Vitamin D 
Diet Drugs 
Saturated fats, Homocysteine Antihypertensive drugs, Statins, HRT, NSAIDs 
Others  
Depression, Traumatic brain injury, Occupational exposure (heavy metals, ELF-EMFs), Infective 
agents (herpes simplex virus type I, Chlamydophila pneumoniae, spirochetes) 
Combined effect  
Increased risk Decreased risk 
Genetic and environmental factors in midlife Genetic and environmental factors in midlife 
ApoE ε4 magnifies the effect of high alcohol 
intake, smoking, physical inactivity and high 
intake of saturate fat 
High education level reduces the negative effect of 
ApoE ε4 
Physical activity counteracts the risk due to ApoE ε4 
 
Vascular and metabolic factors in midlife 
Co-occurrence of hypertension, obesity, 
hypercholesterolaemia and/or physical inactivity 
Environmental factors in midlife 
High level of complexity of work modulates the 
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has an additive effect 
Vascular and metabolic factors/diseases in late-life 
Higher risk in individuals with brain 
hypoperfusion profile: chronic heart failure, low 
pulse pressure, low diastolic pressure 
Higher risk in individuals with atherosclerosis 
profile: high systolic pressure, diabetes mellitus 
or prediabetes, stroke 
increased dementia risk due to low level of education 
Genetic and environmental factors in late-life 
Active leisure activities or absence of vascular risk 
factors reduces the risk due to ApoE ε4 
“Risk and protective factors for dementia and Alzheimer’s disease have been investigated, and there are greater 
and lesser degrees of evidence to support these various factors. APP, amyloid precursor protein; ApoE, 
apolipoprotein E; BMI, body mass index; CLU, clusterin; CR1, complement component receptor 1; ELF-EMF, 
extremely low-frequency electromagnetic field; HRT, hormone-replacement therapy; NSAID, non-steroidal 
anti-inflammatory drug; PICALM, phosphatidylinositol binding clathrin assembly protein; PUFA, 
polyunsaturated fatty acid; SES socioeconomic status; TOMM40, translocase of outer mitochondrial membrane 
40 homolog; TREM2, triggering receptor expressed on myeloid cells” (courtesy Dr Francesca Mangialasche). 
The table is reprinted from the review article Dementia prevention: current epidemiological evidence and future 
perspective, Mangialasche et al, 2012 in Alzheimer Research& Therapy Journal[191]. 
1.2.3 Pathophysiology of Alzheimer’s disease 
The gross pathological feature in dementia in general and AD in particular is a widespread 
brain atropy due to massive neuronal loss. Extracellular amyloid plaques formation and 
intracellular neurofibrillary tangles (NFT) represent the main pathological hallmark of AD[182]. 
They are not completely two separate pathological entities, since studies have shown that amyloid 
pathway could enhance hyperphosophorylation of the tau protein, which is a main and early step 
in the formation of NFT[192]. 
The amyloid cascade hypothesis, postulated by John A. Hardy and Gerald A. Higgins in 
1992, suggested that one of these multiple amyloid species, resulted from the amyloidogenic 
APP-processing pathway, initiates a neurotoxic sequence of events that eventually leads to 
neuronal loss and accumulation of the amyloid species in plaques[193]. This sequence of events 
in amyloid hypothesis is illustrated in Figure 1.3. 
This hypothesis has several supporting data during the timeline from the introduction of the 
hypothesis till the most recent clinical trials for the emerging disease-modifying pharmaceutical 
agents[192]. For example, it was shown that mutations affecting the rate of cleavage of the APP 
could lead to the familial early onset type of AD[194]. Another support to this hypothesis, is the 
high incidence of AD-like neuropathology in the trisomy 21 (Down syndrome), where 3 copies 
of the APP gene are carried in chromosome 21[195]. Finally, the increased clearance of amyloid 
species reduces amyloid aggregations and improvement in cognitive decline in patient treated 
with the immunotherapy Aβ monoclonal antibodies[192]. The genetic polymorphism (A673T) in 
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the gene encoding for APP, results in lower loads of Aβ peptides and better cognitive outcomes 
in both healthy and AD patients[196]. 
 
 
Figure 1.3 The amyloid cascade hypothesis postulates neuronal death and synaptic dysfunction 
as a result of toxic amyloid mediators, mainly the Aβ oligomer. Reprinted from The Lancet, Volume 377, 
Clive Ballard et al, 2011, Alzheimer’s disease, page number 1020.Copyright (2016), with permission from Elsevier[193]. 
 
The microtubule-associated protein, tau, is the second main protein implicated in the 
pathogenesis of AD[197]. In AD, the hyperphosphorylated tau aggregates in the cytoplasm. This 
consequently affects the assembly of the microtubules that accumulate in the intracellular space 
in form of NFT and eventually leads to synaptic dysfunction and neurotransmission 
disturbances[197]. The release of tau to the extracellular space cleft is proposed as a mechanism 
that links pathology and serotonergic disturbances in AD[198]. Different staging systems are used 
to classify the hierarchical involvement of AD neuropathology in the brain. Currently, the Braak 
system for the NFT progression[199], the National Institute on Aging (NIA), Thal amyloid 
staging[200], and the Consortium to Establish a Registry for Alzheimer Disease criteria (CERAD) 
for neurotic plaques are used for staging of AD neuropathology[201]. 
 Disturbances in the neuro-inflammatory pathways, lipid metabolism, neurotransmitter and 
oxidative stress play an important role in the pathogenesis of AD as shown in Figure 1. 4 
   21 
 
Figure 1.4 Molecular mechanisms involved in neuronal death in AD[190] (Courtesy Dr Angel Cedazo-
Minguez), permission from the publisher John Wiley and Sons. 
1.2.4 Clinical features and clinical diagnosis 
The pathology of AD starts long before the appearance of the clinical symptoms, and the 
preclinical period of AD makes the onset of the disease like an iceberg phenomena[202]. In 
dementia, this period is followed by a phase of symptomatic decline in cognitive functions called 
mild cognitive impairment (MCI). Subjective cognitive impairment (SCI) and MCI are two stages 
preceding the full-blown picture of dementia. SCI is defined as a period where the objective 
assessment is not showing evidence of cognitive impairment despite the subjective complaints 
from the patient or his family. 
Recently, “the consecutive 3-stage model” proposed SCI as an early stage of dementia that 
lead to MCI and eventually dementia of AD[203]. The proposed time-line for different AD 
stages compared with the course of cognitive decline in normal aging is shown in Figure 1.5 
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Figure 1.5 The clinical course model of cognitive decline rates in different AD stages[202]. 
Reprinted from Sperling et al, 2011, with permission from the publisher Elsevier. 
 
AD is characterized by the disturbances in cognition, behavioral and impairment in 
functions needed for daily activities and complex tasks. The clinical diagnosis enables the 
physicians to reach a probable diagnosis and the definite diagnosis is only possible after 
postmortem histopathological studies[182, 204]. 
Multiple mental functions are affected in AD dementia. Importantly, the disease affects 
higher brain functions such as planning, problem-solving ability and judgment. Other cognitive 
domains that might be affected in AD are memory, language, the ability to identify objects even 
in the lack of sensation disturbances (agnosia) and the ability to perform familiar task 
(Apraxia)[204]. Objective decline in the neurocognitive domain measured by standardized 
neuropsychological tests are required for AD diagnosis[204]. 
In the updated protocol for clinical diagnosis of AD and according to the new guidelines 
from the Diagnostic and Statistical Manual of Mental Disorder from the American Psychiatric 
Association 5th edition (DSM-V), the memory deficit is not mandatory for inclusion in dementia, 
which is now named neurocognitive disorders (NCDs). In this new protocol, the demarcation 
between the severity classes is the preservation of an acceptable functional level[205]. The 
emergence of the term NCDs and the removal of the necessity for memory deficit in diagnosing 
NCDs are the main differences between DSM-V and DSM-IV[205]. The criteria for AD-
dementia in ICD 10, the international classification of diseases adopted by the World Health 
Organization WHO, require cognitive decline in the absence of consciousness disturbances, 
gradual onset of symptoms and also the absence of structural brain lesions together with the 
exclusion of other organic cause of other dementia[206]. 
Many neuropsychological tests are commonly performed to evaluate and diagnose dementia. 
The clinical evaluation starts with the history taking and recording of the subjective cognitive-
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related complaints from the patients. However, objective cognitive assessments and 
supplementary biomarkers including brain imaging are important to differentiate AD from other 
types of dementia. The revised international working group (IWG-2) criteria for typical AD 
include objective impairment in the episodic memory, PET evidence of amyloid brain pathology, 
typical AD CSF profile and autosomal dominant mutation of familial AD[207]. 
The biomarker profiles are indicative of underlying pathology (see section 1.2.5). However, 
there are some limitations to the diagnostic utility of biomarkers and neuropsychological test. 
Cognitive status is usually screened by the Mini-Mental State examination (MMSE), which 
provides a simple, rapid, practical and cost-effective clinical evaluation for the cognitive function. 
The test has a total of 30 points score and 24 represent the cut-off point for dementia. At the 
cut-off 24: the test has about 80% sensitivity and 90% specificity with modified version of the 
test available in clinical practice to enhance the detection rates such as addition of the clock test 
and the 20-point test[208-210]. MMSE is influenced of depression, the education levels and the 
Intelligence quotient of the participant[211]. The clinical dementia rating (CDR) is a scale used to 
objectively stage the severity of dementia. It is a semi-structured interview contains questions that 
evaluate the subjective memory complains from the informant, orientation, judgment, problem 
solving, abilities to independently perform household tasks and the interactions between the 
informant and his/her society[212]. There are wide ranges of brief cognitive tests; and their use is 
dependent on the reference standards, e.g. ICD10 or DSM-V, the type of dementia diagnosis and 
the country own national guidelines[210]. 
There is wide range of clinical tests depending on the diagnostic protocol in different health 
institutions. Tests that basically designed to be used at primary care services include Memory 
Impairment Screen (MIT)[213], specialized dementia clinics such as Brief Alzheimer screen 
(BAS)[214], Montreal cognitive Assessment (MoCA)[215] and abbreviated mental test (AMT), 
while validated for dual use in both primary and specialized settings like Addenbrook Cognitive 
examination (ACE) and the Clock drawing test[210]. 
Behavioral and psychiatric symptoms of dementia (BPSD) are frequently observed in AD 
and may require pharmacological intervention[216]. Their types and severities depend on the 
stage of AD. For example depression, anxiety, apathy and irritability are the most common BPSD 
symptoms in early AD, while delusion, agitation, sleep disturbances, hallucination and aggressive 
behavior are mainly observed in the intermediate to advanced stages of AD after more than 3-5 
years following the onset of dementia[216].  
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1.2.5 Alzheimer’s disease biomarkers 
A biomarker is defined as measurable indicator for biological or pathological process used in 
clinical and research setting to monitor the progress of a disease or a response to an 
intervention[217]. In AD, biomarkers that reflect the disease pathology could be broadly divided 
into biochemical biomarkers and imaging biomarkers. Combination of these is used nowadays in 
memory clinics to confirm the clinical suspicion when AD diagnosis is probable[218].  
The core biochemical markers for AD are Aβ42, total tau (t-tau) and phosphorylated tau, (p-
tau) while promising biochemical markers for AD derived from synaptic structures, neuronal 
axons or derived from the cell bodies of the neuron (soma) are currently investigated[218].  
CSF represents the biomarker compartment for neurodegeneration in general and AD in 
particular. Accumulating reports indicate the validity of the CSF tau and Aβ42 in the detection of 
AD[219]. AD is characterized by low CSF Aβ42 levels, which might reflect the deposition of this 
peptide in the brain and not necessarily the neurodegeneration process[218-220]. However, this 
pattern of low CSF Aβ42 is not specific to AD and is found in other neurocognitive diseases 
such as DLB, vascular dementia (VaD) and FTD[219]. In addition, other β-amyloid species are 
also used as CSF biomarkers for AD and the reduction of the ratio Aβ42/Aβ40 is used as early 
marker of AD[219].  
The CSF total tau (t-tau) level, a marker of neurodegeneration, is increased in AD[221, 222]. 
This pattern, similar to Aβ42 pattern, is not pathognomonic for AD. Higher CSF t-tau levels are 
reported in VaD and FTD[220, 222]. Although NFL is not a core CSF biomarker is, among 
others, an emerging AD CSF biomarker[223] 
As, phosphorylation of tau protein is believed to be the earliest step in tau aggregation and 
the subsequent formation of NFT[197], CSF-phosphorylated tau is high in AD[220]. Common 
sites of tau phosphorylation’s are at the threonine amino acid at residues 181 and 231, serine at 
positions: 199, 235, 396 and 404[219, 224]. CSF p-tau is not elevated in FTD and so p-tau has the 
advantage from other AD CSF-biomarker in its ability to discriminate AD from other type of 
dementia[220, 221]. The levels of CSF biomarkers are affected by different factors such as the 
neurodegenerative process, neuropsychiatric symptoms such as depression and the ApoE 
genotype[225]. People homozygous for ApoE ε4 allele have lower CSF Aβ42 compared to 
heterozygous and normal control[226]. Moreover, the interpretation of CSF findings in cases 
with mixed pathology, such as combinations of DLB and AD, is an additional challenge to their 
clinical applications. 
Imaging techniques are used to evaluate structural alterations and functional characteristics 
in AD research and diagnosis[227]. Atrophy of the medial temporal lobe, particularly the 
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hippocampal, is strong anatomical clue for AD. Structural brain studies using magnetic resonance 
imaging (MRI) have revealed a correlation between CSF biomarkers and hippocampal atrophy in 
AD[228]. However, the volume of the hippocampus is affected by depression, which is a 
common risk factor, symptom or consequence of depression[229]. Functional imaging also has a 
promising role with the discovery of new tracers specific to tau[230] or Aβ[231], as well as the 
improvement in the resolutions of the new generations of PET scanners. The relationship 
between AD-biomarkers and the disease progression is shown in Figure 1.6. The figure 
illustrates a hypothetical model that describes changes of AD imaging, laboratory biomarkers 
across the progression phases of AD dementia[232]. 
 
 
Figure 1.6 The interactions between biomarker and cognitive decline in AD[232]. Reprinted with 
permission from Elsevier, copyright (2016), from Jack CR Jr. et al. 2010, Hypothetical model of dynamic 
biomarkers of the Alzheimer's pathological cascade,  The lancet Neurology. 2010 (9): 119-128. PubMed PMID: 
20083042 
1.2.6 Treatment of Alzheimer’ disease  
The management of AD could conventionally be divided into pharmacological and non-
pharmacological treatments. The non-pharmacological treatments include cognitive training and 
cognitive stimulation strategies. Despite the significant safety and efficacy profiles of 
pharmacological treatment, challenges such as the caregivers lower motivation and lack of 
resources might interfere with the outcome[233].  
Commonly used agent in the medical practice are symptomatic treatments[233]. Drugs that 
increase brain acetylcholine levels, through inhibition of the degrading enzyme the acetyl choline 
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esterase, such as donepezil or galantamine, are used in AD with a good clinical effect in terms of 
cognition and function[234]. 
Symptoms such as agitation and aggression during the course of disease require optimal 
control with antipsychotic medication for patients and caregiver safety[182]. This usage is limited 
by both acute and chronic side effect of both classical and atypical neuroleptic medications[182]. 
Antidepressant are also frequently used in AD[182], and the prolonged use of SSRIs promotes 
neurogenesis in mice models of AD[235]. The use of SSRIs is associated with lower cognitive 
decline and higher levels of brain 5-HT metabolites in AD. However, a multi-center, double 
blinded and randomized clinical trials indicate not only the lack of effect when using sertraline 
but also increase incidences of side effects[236]. 5-HT6 blockade is an emerging cognitive-
enhancing strategy and the objective is to indirectly increase the acetylcholine release by blocking 
the inhibitory receptor 5-HT6, resulting in dual antidepressant and beneficial cognitive 
effect[237]. 
Immunotherapy for AD implies the use of passive or active immunizations to take 
advantage of antibodies against tau or β-amyloid proteins in order to facilitate the clearance, 
reduce the aggregations of amyloid protein and reduce the brain amyloid and tau deposition[234]. 
Until very recently, no promising results were revealed from strategies of disease modifying 
drugs targeting Aβ synthesis by inhibiting the gamma-secretases and β-secretase or by inhibiting 
tau phosphorylation[238]. This might be attributed to the diffuse functions of these enzymes and 
to multiple systemic side effects when they are pharmacologically modulated. However, a recent 
Phase 2b study showed that amyloid immunotherapy might not only reduce the level of amyloid 
plaques but also showed promising clinical improvements[239]. Immunotherapy against tau is 
relatively new compared to the preceding research and trials for β-amyloid proteins[238]. 
In addition to the high cost of immunotherapy drug development, factors such as difficulties 
in designing a pharmaceutical that can cross the blood brain barrier and the high failure rates due 
to issues related to patient safety and drug tolerability, contribute to the innovation gap in this 
field[238, 240]. Many amyloid-based immunotherapy clinical trials were stopped due to the 
development of aseptic meningitis and meningoencephalitis. Although the incidence of this side 
effect is not high, it is a serious life-threatening condition that may require termination of the trial 
due to patient safety concerns[238]. Pharmaceutical agents licensed for the clinical use or on 
clinical trial in AD are summarized in Table 1.2[182].  
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Table 1.2 Treatment of AD 
 Drugs Status Evidence 
Symptomatic treatments 
Cholinesterase 
inhibitors 
Donepezil, 
rivastigmine, 
galantamine 
Licensed for mild-to-
moderate Alzheimer's 
disease 
More than 30 placebo-controlled randomised 
controlled trials, mainly of 6 months duration in 
patients with mild-to-moderate Alzheimer's 
disease (MMSE 10–26). Significant benefits in 
cognition, function, and global outcome, with 
MMSE gain of 1·5–2 points over 6–12 months. 
Several studies suggest similar benefit in severe 
Alzheimer's disease 
NMDA 
receptor 
antagonist 
Memantine Licensed for moderate-
to-severe Alzheimer's 
disease 
Significant benefit in cognition, function, global 
outcome, and neuropsychiatric symptoms over 6 
months in three trials of moderate-to-severe 
Alzheimer's disease 
Treatments for neuropsychiatric symptoms 
Atypical 
antipsychotics 
Risperidone, 
quetiapine, 
olanzapine, 
aripiprazole 
Risperidone licensed for 
short-term treatment of 
severe aggression in 
Alzheimer's disease; 
other treatments are 
used off licence 
Significant but modest efficacy for the treatment 
of aggression (SES 0·2–0·25) and psychosis (SES 
0·15–0·2) over 6–12 weeks. Limited evidence of 
long-term benefits. Atypical antipsychotics 
associated with significant increase in stroke (RR 
2·5–4·0) and death (RR 1·5–1·8) 
Antidepressants Citalopram, 
sertraline 
All antidepressants used 
off licence in 
Alzheimer's disease 
Evidence not clear-cut. The largest trial with 
sertraline suggested no benefit for the treatment 
of depression in patients with Alzheimer's 
disease.Severe depression should be treated, 
probably with a selective serotonin reuptake 
inhibitor 
Anticonvulsants Carbamazepine Used off licence There is preliminary evidence from small 
randomised controlled trials that carbamazepine 
might be an effective treatment for agitation or 
aggression in Alzheimer's disease 
Proposed disease-modifying treatments 
Immunotherapy Bapineuzumab In phase 3 clinical trials Passive immunotherapy treatments show some 
benefit in animal models of Alzheimer's disease.80 
Bapineuzumab is in phase 3 clinical trials 
Sectretase 
inhibitors 
Tarenflurbil, 
semagacestat 
In phase 3 trials Tarenflurbil failed in phase 3 trials.81 Semagacestat 
is in a phase 3 clinical trial programme at present 
 
Amyloid 
aggregators 
Tramiprosate Discontinued Failed in phase 3 trials 
Copper or zinc 
modulators 
PBT2 Phase 2 clinical trials PBT2 resulted in a decrease in cerebrospinal fluid 
amyloid and provided significant clinical benefit in 
a phase-2 clinical trial. Phase 3 trials are awaited 
Tau aggregation 
inhibitors 
Methylthioninium 
chloride 
Phase 2 clinical trial A promising phase 2 trial suggested significant 
cognitive benefit over 52–78 months of follow-up, 
but there were major methodological limitations 
GSK3 
inhibitors 
Lithium Early-phase clinical trials The mood stabilising drug lithium inhibits the 
enzyme GSK3 and reduces the phosphorylation 
of tau in animal models. Early-stage clinical trials 
are in progress 
Natural 
products and 
vitamins 
Vitamin E, ginkgo 
biloba, omega 3 
fatty acids, and 
docosahexaenoic 
acid 
Phase 2 and phase 3 
clinical trials 
Despite initial promise, a more recent randomised 
controlled trial in mild cognitive impairment did 
not report any benefit with vitamin E. 
A meta-analysis suggested ginkgo biloba might 
provide moderate benefit, but a large randomised 
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trial did not show any advantage of ginkgo biloba 
compared with placebo 
A large randomised controlled trial of omega 3 
fatty acids did not report any benefit on function 
or cognition, but did suggest some possible 
benefit on neuropsychiatric symptoms in a post-
hoc subgroup analysis. A National Institute on 
Aging phase 3 trial of docosahexaenoic acid is in 
progress 
MMSE=mini mental state examination. SES=socioeconomic status. RR=relative risk. GSK3=glycogen synthase 
kinase 3. Adopted from The Lancet, Volume 377, 2011. Courtesy professor Clive Ballard, Alzheimer’s disease, page number 1020. 
Copyright (2016), with permission from Elsevier[182]. 
1.2.7 Peripheral biomarkers in Alzheimer’s disease 
There are many advantages with peripheral biomarkers extracted from blood. This could 
provide an easy, non-invasive and cost affordable measure to diagnose or monitor AD pathology. 
However, the biological partition made by blood–brain barrier will hinder the assumption of 
correlation between CNS and blood levels of such biomarkers. Moreover, CNS-derived proteins 
will be subjected to more degradation when they are released into blood than when they are 
confined to CNS. 
Due to alterations in the biological characteristics of different blood cells and blood-related 
molecules in AD, many blood constituents are studied for a peripheral biomarker candidate. 
These alterations might be in the amyloid content, production of particular blood cell type or in 
other intracellular biological pathway such as the inflammatory pathways, immune response and 
neurotransmitter systems. Again, these changes are not specific for AD. 
The non-specificity of these biomarkers is due to the fact that wide range of physiological 
and pathological conditions are associated with alterations in the inflammatory biomarkers at the 
blood level. Furthermore, ageing is associated with disturbances in the balance between the 
inflammatory and the resolution mechanism of inflammation, which could be detected in the 
blood[241]. This imbalance might be exaggerated in AD, where more neuroinflammation and less 
effective brain-specific resolution of the inflammatory response are observed. 
1.2.7.1 Plasma biomarkers and Alzheimer’s disease 
The plasma, through blood brain barrier (BBB) and pial arteries around the meninges, 
represents the compartment for amyloid clearance from brain and CSF[242, 243]. Several plasma 
proteins are investigated for a possible peripheral biomarker potential[244]. 
Plasma levels of Aβ40 and Aβ42 increase with age and correlate with their counterpart CSF 
levels, which indicates sequential handling of Aβ peptides from the brain to the plasma via the 
CSF[245]. In addition, plasma levels of Aβ40 and Aβ42 are high in early AD and also high in 
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asymptomatic subjects with high risk for dementia[245]. Moreover, elevated levels of plasma 
Aβ42 are associated with increased mortality in AD[246]. 
Interestingly, reports have shown also an association between the ApoE genotype and the 
plasma Aβ. This relationship depends on the type of Aβ and absence or presence of AD 
pathology[247]. In agreement with this, the meta-analysis performed by Hye A et al, 2014 has 
revealed that plasma ApoE levels correlate with both hippocampal and whole brain atrophy[244]. 
ApoE ε4 allele-positive AD patients have higher plasma Aβ40, but not Aβ42, compared to 
the elderly non-demented controls[247]. However, plasma Aβ40 is not associated with MMSE 
and other AD biomarkers in AD in this study. Plasma biomarkers are not yet clinically useful in 
AD detection despite the compelling evidence of the association between plasma and CSFAβ. 
Moreover, CSF Aβ biomarkers are superior to that of plasma in the prediction of conversion 
from MCI to dementia[248]. 
Plasma tau and p-tau were also investigated for a potential peripheral biomarker role in AD. 
In contrast to lack of significant difference in tau levels between healthy controls and MCI group, 
the AD-CSF pattern shows significantly higher t-tau levels compared to both MCI and healthy 
controls[249]. These findings suggest that total tau levels in plasma are not an early disease 
biomarker of AD and the benefit of it could be restricted for diagnostic purposes[249]. 
Limitations of the plasma AD biomarkers include the technical difficulties in their measurements 
due to their low concentrations in plasma, high cost and the variability of results between 
different laboratories[247]. 
1.2.7.2 Plasma and serotonin metabolites in Alzheimer’s disease 
High performance liquid chromatography apparatus followed by electrochemical detection 
(HPLC-ECD) provides a robust and reproducible mean for measurement of body fluid 5-HT 
and 5-HIAA[250]. The seasonal variation in plasma 5-HT metabolites levels should be taken into 
consideration to avoid possible misinterpretation[251]. Other factors such as ethnic variations, 
type of diet, nutritional status, underlying chronic disease and use of particular medication could 
influence the plasma 5-HT levels. There are different neuropsychiatric conditions with reported 
changes in plasma 5-HT metabolites concentration such as depression, bipolar disorder and 
autism, which can coincide with dementia or present as differential diagnosis in the clinical 
workup of dementia[252, 253]. 
Although there is no compelling evidence indicating that plasma 5-HT correlates with CSF 
5-HT level in human, a correlation between 5-HIAA and the 5-HT turnover, i.e. the 5-HIAA/5-
HT ratio, between plasma and CSF has been reported[254]. 
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The plasma as extracellular compartment contains different biological systems with a wide 
range of molecules, including signaling molecules, and host complex interactions between these 
different systems. The 5-HT metabolites are involved in biological functions produced mainly by 
other plasma systems such as immune function. Plasma levels of tryptophan decrease with aging 
and inversely correlate to levels of particular cytokines immune mediators such as interleukin 6 
and 8 (IL6 and IL8)[255].  
These findings illustrate the importance of the interaction between 5-HT and immune 
system in an inflammatory and age-related disorder such as AD[255]. Surprisingly, Higher plasma 
5-HT levels were shown in AD, while no change in 5-HIAA is detected in one report[250]. 
1.2.7.3 Leucocytes and Alzheimer’s disease 
Lymphocytes are central in the pathogenesis of chronic inflammatory conditions and the 
lymphocyte subtypes CD40 and CD40L are recruited centrally for the amyloid-induced microglial 
activation process[256, 257]. Levels of the soluble CD40 in the blood are higher in AD compared 
to non-AD dementia[258]. Lymphocytes, particularly CD95, are also associated with alteration in 
apoptotic activity and oxidative stress in AD and their peripheral levels are elevated in AD[257, 
259]. In addition, there are non-conclusive reports discussing alteration in the central and 
peripheral levels of CD4 and CD8 in AD[257, 260]. Taken together, these reports together reflect 
the antigenic over-stimulation of the adaptive immune system in AD[261]. This is important to 
the interleukin and antibody profiles that modulate T-helper, T-suppressor and T-cytotoxic cells 
and regulate both the humoral and cellular immunity[257]. Although both T-lymphocytes and B-
lymphocytes are reduced by AD pathology[262], no correlation was found between the total 
lymphocyte count and the cognitive decline in AD[263]. 
B-lymphocytes mature into plasma cells and produce clone-specific antibodies in response to 
stimulation with non-self antigens presented to them by the antigen presenting cells (APCs) in 
association with the major histocompatibility complex type 2 (MHCII). Levels of circulating 
autoantibodies from Immunoglobulin G (IgG) directed against AD-related pathological antigen 
are high in AD, which suggest an autoimmunity-like mechanism in AD due to lack of tolerance 
for particular self-antigens[264]. Profiles of phenotypic changes in blood cells could be dependent 
on the progression of cognitive symptoms and severity of dementia. Higher levels of 
lymphocytes and lower polymorph nuclear cells (neutrophils) are seen in MCI compared to age 
and sex matched healthy controls[262]. 
Alteration in other types of leucocytes, in terms of functional and expression profiles, are 
also reported in AD. Other peripheral cells affected by AD-pathology are natural killer cells 
(NKC), red blood cells and platelets[257]. 
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1.2.7.4 Red blood cells and Alzheimer’s disease 
Red blood cells (RBCs) or erythrocytes are non-nucleated cells characterized by wide-
spanning cell membrane surrounds the cell in a biconcave-shape manner[265]. RBCs, due to the 
hemoglobin pigment, represent the body intravascular delivery system for the oxygen and 
nutrient to the tissue[265]. Patients with abnormalities in the synthesis of RBCs or hemoglobin 
have inadequate oxygen supply to tissues and present clinically with hypoxia. In addition, chronic 
hypoxia implies an oxidative stress for neuronal cells. 
The oxygen-carrying capacity and gaseous exchange efficiency of RBCs are impaired by the 
peripheral β-amyloid (Aβ) peptides in the blood[242]. This is due to the fact that soluble forms of 
Aβ peptides lead to hemolysis of RBCs in contrast to non-soluble forms[266]. However, 
enhancing polymerization of Aβ peptides into fibrillar structure prevents this amyloid-induced 
hemolysis of RBCs[242, 266]. 
Reports have shown that human erythrocytes contain higher Aβ40 and Aβ42 peptides levels 
than those in plasma, which suggest that RBCs represent the subsequent clearance pool for 
plasma Aβ[242]. The interaction between plasma amyloid species and erythrocytes is relevant to 
AD pathology. Levels of Aβ peptides in RBCs are associated with oxidative stress[242]. 
Furthermore, significant correlations were shown between the plasma levels and erythrocytes 
levels of Aβ42 and Aβ40. Relevantly, binding of these Aβ peptides to RBCs increases with 
aging[242]. In AD, this interaction is more active in low- density RBCS[267]. Intuitively, the 
interaction between plasma and RBCs amyloid pools depends also of the physical and 
biochemical characteristics of Aβ peptides such as lipid solubility, presence of hydrophobic 
amino acids and the plasma concentrations[242, 268]. 
1.2.7.5 Physiological aspects about platelets 
Platelets are derived from the bone marrow precursor, the megakaryocyte cell. Similar to 
RBCs they are enucleated peripheral blood cells. They are involved in different physiological and 
pathological process such as coagulation hemostasis, inflammation and hypersensitivity reactions 
and atherosclerosis[10]. 
Functional and structural molecules are localized in the platelet’s cell membrane, plasma, 
dense granules, α-granules and the platelets-surface associated glycoproteins[10]. The platelet 5-
HT is transported from the cytoplasm to be stored in the dense granules through specialized 
transporters[269]. In particular situations, platelets are activated to release the stored vasoactive 
amines after exposure to von Willebrand factor (vWF) in the reticuloendoethelial system 
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(RES)[270]. P-selectin is contained in the α-granules and considered as a marker for platelets 
activity that is conventionally measured by flow cytometry or ELISA[271]. 
1.2.7.6 Platelets and Alzheimer’s disease biomarkers 
Platelets have less proteomic variability, more stable and reproducible AD biomarker profiles 
compared to plasma[272]. Platelets are considered as peripheral neuropharmacological model 
with many biological similarities to neurons[273]. The advantages of this model is that they can 
be obtained by less invasive means and can be characterized with simple laboratory methods. 
The similarities between platelets and neurons are relevant to AD. Platelets can be used in 
studying expression of relevant amyloid species, inflammation, oxidative stress markers, 5-HT 
trafficking, transmission and pharmacological modulations[274]. The serotonergic similarities to 
neurons include 5-HT uptake from the plasma into platelets intracellular compartment, 5-HT re-
uptake modulation by antidepressant and antipsychotics, modulation of the intracellular granules 
by the pharmacological modulations of 5-HT receptors[273, 274]. 
Still, there are a number of limitations for using platelets as a neuropharmacological model in 
AD. First, the amyloid content of the platelets depends on the interaction between platelets and 
collagen and hence amyloid levels are not homogenous in all platelets sub-populations[275]. In 
addition, platelets activity influence platelet-derived AD biomarkers, 5-HT biomarkers and the 
pharmacological modulation of platelet 5-HT[273]. Important differences between platelets and 
neurons are the inability of platelets to synthesize or degrade 5-HT due to the lack of MAO-
A[276]. 
The biological roles of Aβ in platelets are diffuse and not fully understood yet. However, it is 
known that platelets release Aβ peptides, which stimulate platelet activity[276, 277]. Although 
different candidate biomarkers were investigated for potential platelets-derived biomarker, only 
amyloid precursor protein APP and MAO-B are classified among the most reliable AD-related 
platelets biomarkers[276]. 
Platelets express all secretase enzymes that are needed to produce the similar neuronal 
amyloid processing. Moreover, the pattern of inhibition of the non-amyloidogenic pathway that 
takes place in platelets in early AD is similar to that occurring in brain[276]. Because of the 
downregulation of the activity of the responsible enzyme α-secretase, less production and release 
of soluble APP species is seen in platelets in early stages of AD[278]. This is mirrored by 
increased activity of the amyloidogenic pathway including increased β-secretase activity in 
AD[278]. The proteomic findings from APP isoforms are consistent with the gene expression 
   33 
profiles of APP mRNA[274]. The potential platelet-derived AD biomarkers are shown in Figure 
1.7[276]. 
 
Figure 1.7 Platelets-derived Alzheimer’s disease biomarkers. “Adopted from Veitinger et al, 2014, Acta 
Neuropathologica Communicartion.Open access through The Creative Commons Public Domain Dedication waiver, 
© Veitinger et al.; licensee BioMed Central Ltd. 2014”[276]. 
1.2.7.7 Platelets serotonin in Alzheimer’s disease 
Accumulating data suggest the reliability of platelets 5-HT as a peripheral biomarker in 
AD[276]. This is attributed to the fact that 5-HT transmission, packing in granules or vesicles, 
expression of 5-HT receptors and response to antidepressant and antipsychotic are comparable 
between platelets and neuronal cells[274, 276]. 
Although the main impact of AD on serotonergic system is seen in RN, serotonergic 
disturbances are not limited to neuronal cells[41]. Alterations of serotonergic pathway in platelets 
are repeatedly reported in AD, which include alteration in 5-HT2A binding, SERT uptake of 5-
HT and the 5-HT metabolites profiles[276]. However, results from 5-HT levels in platelets in AD 
showed inconsistent data. The findings extracted from the literature fluctuate between higher, 
lower or no differences between platelets 5-HT in AD and their corresponding normal 
controls[250, 279, 280]. Similar inconsistent data is also reported regarding alteration of 5-HT 
uptake by platelets in AD[276]. Different factors affect 5-HT uptake or concentrations in AD 
such as depression, psychotic symptoms, platelets density and platelets activity[280-282]. Reports 
suggest an association between cognitive decline in late AD stages and lower platelets 5-HT 
levels[277, 279]. Moreover, platelets 5-HIAA levels are not reduced in AD[250]. While some 
reports indicate that the activity MAO-B is increased in AD in both platelets and brain 
neurons[250, 276, 281, 283], other reports indicate no alteration in MAO-B activity in AD[284, 
285].   
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1.3 Brain serotonergic system in Alzheimer’s disease 
There are multiple factors that contribute to the brain serotonergic alterations in AD. First, 
there is loss of 5-HT cell bodies and damage to 5-HT neurons from RN and disturbances in 5-
HT transmission[41]. Moreover, alterations of 5-HT receptors expression and/or function are 
observed in AD[41, 286]. Reduction in SERT expression, change in frequency of SERT genetic 
polymorphism and change of serotonin reuptake pattern could also contribute to disturbances of 
5-HT hemostasis in AD[287]. The molecular aspects of the positive influence of 5-HT on 
neuronal protection against AD pathology are illustrated in Figure 1.8. 
 
 
Figure 1.8 The neuroprotective mechanism of 5-HT in AD. Adopted from The serotonergic system 
in ageing and Alzheimer’s disease, Volume 99, page number 26 Rodriguez et al, 2012, Progress in 
Neurobiology. Copyright (2016), with permission from Elsevier 
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1.3.1 Serotonergic neuronal loss in Alzheimer’s disease 
Postmortem brain tissue and genetic animal models were used to understand how AD 
pathology affects 5-HT neurons. The methods used to illustrate brain expression of 5-HT 
markers include classical staining, IHC and PET. In contrast to normal aging where the 5-HT 
neurons are relatively stable until late in life[288], significant loss of 5-HT neurons was observed 
in AD[289]. However, age is an important factor in determining the impact of AD on 
serotonergic neurons. The more the advanced age at the onset of AD, the more the severe the 
impact of AD on RN[41]. 
RN which represents the anatomical location for the cell bodies of serotonergic neurons[42], 
is significantly affected by AD pathology and its involvement is associated with AD symptoms 
progression[290]. Furthermore, 5-HT neurons projecting to the hippocampus from the DRN are 
among the highest affected serotonergic projections by NFT-AD pathology[41, 291]. However, 
there is increased 5-HT neuron sprouting, detected by SERT staining, in hippocampus suggestive 
of compensation for 5-HT neuron loss[292, 293]. 
On the other hand, alteration in the serotonin content and 5-HT transmission might 
influence the amyloid-related pathology[294]. Triple transgenic AD mice subjected to high 
tryptophan diet showed lower amyloid burden in the hippocampus CA1 area compared to animal 
subjected to normal or low tryptophan diet[294]. 5-HT modulates the excitatory neural activities 
in the entorhinal cortex[295]. Therefore the availability of 5-HT affects no only AD pathology 
but also physiological functions of memory related brain areas. 
1.3.2 Alterations of 5-HT and 5-HIAA in Alzheimer’s disease 
Reduction of 5-HT and 5-HIAA are consistently reported from different brain area and 
shown to correlate with dementia progression and particular BPSD[41, 296]. Brain areas with 
lower 5-HT and 5-HIAA levels include hippocampus, basal ganglia, frontal cortex, temporal 
cortex and amygdala[41]. However, other reports suggest equal to higher levels of 5-HIAA in AD 
in the frontal, parietal and temporal cortex in human[297]. The data from 5-HT metabolite in AD 
shows significant variation across different models and intervention techniques. Higher 5-HIAA 
levels are reported in rat model injected with Aβ40 in the dorsal hippocampus, while low levels 
are reported in AD mice model[298, 299].  
Table 1.3 summarizes the human and animal studies highlighted 5-HT and 5-HIAA in 
AD[41].  
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Table 1.3: AD-associated changes in the levels of 5-HT/5-HIAA: post-mortem and animal model studies. 
Marker/Technique 
Post-mortem studies  
 
Age (years) N (AD) Brain region/levels of 5-HT/5-
HIAA in % of the control 
Reference 
5-HT (HPLC) 82 46 FC – 65 for 5-HT, TC – 49 for 5-HT Palmer et al. 
(1987) 
5-HT (HPLC) 
5-HIAA (HPLC) 
76 17 A – 59 for 5-HT, 50 for 5-HIAA 
DR – 215 for 5-HT, 118 for 5-HIAA 
Burke et al. 
(1990) 
5-HT (HPLC) 
5-HIAA (HPLC) 
81 13 TC – 37 for 5-HT, 63 for 5-HIAA 
CN – 45 for 5-HT, 51 for 5-HIAA 
A – 51 for 5-HT, 57 for 5-HIAA 
P – 64 for 5-HT, 81 for 5-HIAA 
Nazarali and 
Reynolds (1992) 
5-HT (HPLC) 
5-HIAA (HPLC) 
81 20 FC – 94 for 5-HT, 144 for 5-HIAA 
TC – 70 for 5-HT, 117 for 5-HIAA 
Chen et al. 
(1996) 
5-HT (HPLC) 82 17 FC – the paper indicates that the 5-
HT levels were decreased but does 
not provide quantification 
Lai et al. (2002) 
5-HT (HPLC) 
5-HIAA (HPLC) 
81 20 FC – 45 for 5-HT, 47 for 5-HIAA 
TC – 48 for 5-HT, 40 for 5-HIAA 
Garcia-Alloza et 
al. (2005) 
5-HT (HPLC) 
5-HIAA (HPLC) 
74 9 FC – 75 for 5-HT, 99 for 5-HIAA 
TC – 118 for 5-HT, 140 for 5-HIAA 
PC – 55 for 5-HT, 87 for 5-HIAA 
Bowen et al. 
(2008) 
Animal studies 
5-HIAA (HPLC) Transgenic mouse model of AD 
with Aβ pathology 
C – 74* 
H – 67* 
Liu et al. (2008) 
5-HIAA (HPLC) Intrahippocampal injected Aβ rat 
model 
H – 152 Verdurand et al. 
(2011) 
Key: Age: mean age, HPLC: high performance liquid chromatography, 5-HT: 5-hydroxytrptamine, 5-HIAA: 5-
hydroxyindoiatic acid, N: number of AD samples included in the study, FC: frontal cortex, TC: temporal cortex, PC: 
parietal cortex, A: amygdala, CN: caudate nucleus, P: putamen, DR: dorsal raphe nucleus, C: cortex, H: hippocampus, 
nr: notreported. Numbers were estimated from the graphs. Reprinted with permission from Elsevier, copyright (2016). The table is 
reused from the review article The serotonergic system in ageing and Alzheimer’s disease, Volume 99, page number 26, Rodriguez et al, 
2012, Progress in Neurobiology. 
1.3.3 5-HT1A and Alzheimer’s disease 
5-HT1A plays a role in the memory consolidation; it mediates particularly the consolidation 
of learning in both physiological state and cognitive impairment[300]. 5-HT1A is evaluated with 
binding studies, positron emission tomography (PET), or IHC, see down Table 1.4[41]. 
Whereas 5-HT1A antagonists were proposed to improve memory, 5-HT1A agonist 
(tandospirone) showed impairment of explicit memory. Negative correlation was observed 
between explicit memory and 5-HT1A hippocampal expression[301]. In addition, injection of 
Aβ40 in the dorsal hippocampus in a rat model produces a transient increase of 5-HT1A 
expression in astrocytes[298]. Consistent with this data, a negative correlation between the 
hippocampal 5-HT1A binding potential and explicit memory was shown[301]. Another study 
showed that reduction in 5-HT and increased densities of 5-HT1A are correlated with cognitive 
decline in AD[302]. 5-HT1A bindings in the hippocampus are associated with neuropsychiatric 
symptoms, where low 5-HT1A binding particularly associated with depression in AD[303]. Taken 
together, these reports reflect the negative effect of postsynaptic 5-HT1A on memory function 
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through inhibition of hippocampal 5-HT[301]. An increase of 5-HT1A binding in the frontal 
cortex is also reported in AD; however, no correlation with the disease duration, pathological 
markers or neuroleptic medication was found[304]. In contrast, reduction in 5-HT1A densities in 
hippocampal and parahippocampal regions in AD was reported using PET[305]. The same study 
showed increased whole brain 5-HT1A densities in MCI and reduction in AD, which suggest 5-
HT1A as a demarcating molecular marker to differentiate MCI from AD[305]. 
 
Table 1.4: AD-associated changes in 5-HT1A receptors: binding, PET and immunohistochemical studies. 
Radioligand/Marker Age 
(years) 
N  
(AD) 
Brain region/5-HT1A receptor % of 
the control 
Reference 
Binding studies 
[3H]-5-HT nr nr FC – 52 Bowen et al. (1983) 
[3H]-5-HT 79 nr PC – 74 Perry et al. (1984) 
[3H]-5-HT 79 12 FC – 85, TC – 53, H – 60, A – 48 Cross et al. (1984) 
[3H]8-OH-DPAT 72 nr FC – 53 Middlemiss et al. (1986) 
[3H]8-OH-DPAT 82 24 H – 50 Lai et al. (2011) 
[3H]-5-HT 78 13 TC – no changes Cross et al. (1986) 
[3H]-5-HT 72 5 TC – no changes Cross et al. (1988) 
[3H]-5-HT 77 8 H – no changes Jansen et al. (1990) 
[3H]8-OH-DPAT 81 33 FC, TC – no changes Lai et al. (2003a) 
[3H]8-OH-DPAT 82 35 TC – no changes Tsang et al. (2010) 
[3H]8-OH-DPAT 82 17 FC – increased density Lai et al. (2002) 
Positron emission tomography studies 
[18F]MPPF 75 14 H – 73, R – 59 Kepe et al. (2006) 
[18F]MPPF 77 14 H – 87 (aMCI) Kepe et al. (2006) 
[18F]MPPF 72 11 H – 65 Truchot et al. (2007) 
[18F]MPPF 
 
70 10 H, InfOG – decreased binding 
potential 
Truchot et al. (2008) 
[18F]MPPF 73 11 
aMCI 
H – increased binding potential Truchot et al., (2008) 
and Truchot et al., (2007) 
Immunohistochemical studies 
5-HT1A 83 8 PN – reduced density 
VN – reduced density 
R – reduced density 
Yeung et al. (2010) 
5-HT1A 77 11 H – reduced immunoreactivity Mizukami et al. (2011) 
Key: Age: mean age, N: number of AD samples included in the study, BS: binding studies, Au: autoradiography, 
PET: positron emission tomography, IHC: immunohistochemisrty, aMCI: amnesic mild cognitive impairment, FC: 
frontal cortex, PN: pontile nuclei, VN: vagal nucleus, TC: temporal cortex, PC: parietal cortex, A: amygdala, H: 
hippocampus, Neo: neocortex, R: raphe nucleus, InfOG: inferior occipital gyrus, nr: not reported. Reprinted with 
permission from Elsevier, copyright (2016). The table is reused from the review article The serotonergic system in ageing and Alzheimer’s 
disease, Volume 99, page number 26, Rodriguez et al, 2012, Progress in Neurobiology[41]. 
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1.3.4 5-HT1B, 5-HT1D, 5-HT2A, 5-HT4 and 5-HT6 in Alzheimer’s disease 
Despite the importance of 5-HT1B in regulation of multiple neurotransmitters, only one 
report investigating the binding of 5-HT1B in frontal and temporal cortex and implication of 5-
HT1B in cognitive decline is available[286]. The study showed lower density of 5-HT1B in 
frontal and temporal cortex in AD. In addition, they reported a correlation between increase in 5-
HT1B binding and MMSE decline[286]. However, in this study they used [3H]-GR-125743, 
which is a non-specific radiolabelled antagonist that binds both 5-HT1B and 5-H1D[306]. The 
use of PET would provide a powerful tool to evaluate the antemortem levels 5-HT1B in 
dementia. Reduction of cortical 5-HT1B is attributed to normal aging in one PET study[307]. 5-
HT6 pharmacological modulations showed potential therapeutic effects in depression, anxiety 
and metabolic disorder despite the lack of information about the detailed mechanism of 5-HT6 
in neuropsychiatric disorders[308]. 5-HT6 antagonist is a newly emerging strategy of cognitive 
enhancement in AD[308]. This is attributed to the modulation of cholinergic, GABA, glutamate 
systems and a complex downstream signaling pathway. The proposed molecular mechanism of 5-
HT6 blockade in cognitive enhancement is shown in Figure 1.9[309]. 
 
 
Figure 1.9 The biochemical and molecular influence of 5-HT6 blockade on cognitive function. 
Reprinted with permission from Elsevier, copyright (2016), from Codony et al. 5-HT (6) receptor and cognition. Curr Opin 
Pharmacol. 2011 (1): 94-100. PubMed PMID: 21330210. 
 
Brain 5-HT2A expression in AD was assessed by autoradiography, PET and single-photon 
emission computed tomography (SPECT). Consistent reductions of 5-HT2A levels were 
reported in temporal cortex with significant correlation with MMSE decline[41, 310]. 
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Increased activity of 5-HT4 stimulates the non-amyloidogenic pathway through the 
activation of the α-secretase enzyme that favors the production of soluble Aβ species[311]. These 
findings are consistent with promising data from 5-HT4 agonist alone or in combination with 
acetylcholinesterase (AChE) inhibitor as a candidate drug for AD[312, 313]. 
1.3.5 SERT in Alzheimer’s disease 
The genetic polymorphism of SERT influences the pattern of 5-HT transport and thus it 
might aggravate 5-HT deficit in AD[314]. Despite the repeated reports suggesting changes of 
SERT genetic variability to be a predisposing factor to late onset AD[315], no compelling 
evidence that SERT polymorphism plays a significant role in determining the clinical syndrome in 
terms of BPSD in AD exist[316]. Reports about the expression of SERT in human postmortem 
studies indicate a reduction of SERT in frontal, temporal and parietal cortex[41]. However, in a 
triple transgenic model of AD upregulations of SERT and SERT-expressing neurons were 
reported in CA1 area of the hippocampus[292, 293].  
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1.4 Serotninergic system in Lewy body dementia (LBD) 
The term Lewy body dementia (LBD) include both Parkinson disease dementia PDD and 
DLB[317, 318]. As discussed above, serotonergic disturbances exist in different type of 
neuropsychiatric disorders, regardless the underlying pathology. They are seen in VaD, FTD and 
motor neuron disease such as amyotrophic lateral sclerosis (ALS)[41]. Although depression 
represents a logical link between dementia symptoms and serotonergic disturbances, independent 
serotonergic disturbances occur also in dementia patients without depressive symptoms[319]. 
1.4.1 Serotonergic system in Parkinson disease (PD) 
Parkinson’ s disease (PD) is the second most common neurodegenerative disorder in elderly. 
It is characterized clinically by mixture of motor and non-motor symptoms[320]. The motor 
symptoms comprise the classical triad of rigidity, tremor and bradykinesia. Dementia represents 
the most important and common non-motor consequence of PD[321]. PDD is a well-known 
sequel in PD during the disease clinical course. The prevalence of PDD in PD is about 31.1%, it 
accounts for 3% of all dementia cases and 0.5% of population above 65 year old[317, 321]. 
The pathological hallmark of PD is the degeneration of the dopamine-releasing neurons in 
the basal ganglia particularly the degeneration of the striatonigral pathway (SN). Moreover, 
multiple neurotransmitters such as 5-HT and acetylcholine are implicated in the pathogenesis of 
PD[322]. Of note, the basal ganglia receive dense serotonergic projections from RN, which 
inhibit the dopamine release[42, 323]. These projections are affected by the PD-pathology and 
the impact is more severe in PD patients with depression[324]. Basal ganglia’s serotonergic 
alteration in PD is shown in Figure 1.10[324]. 
 
 
Figure 1.10 Comparison of 5HT levels in PD and normal subjects. GPe: globus pallidum pars 
externa, GPi: globus pallidum pars interna, SN: substantia nigra and STN is subthalamic nucleus. Reprinted 
with permission from Elsevier, copyright (2016), from Hout et al. The serotonergic system in Parkinson's disease. Progress in 
Neurobiology. 2011 (95):163-212 . PubMed PMID: 21878363 
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Lower CSF levels of 5-HT and 5-HIAA and the inverse correlations with the progression 
and severity of symptoms in PD indicate the serotonergic deficit in PD[325]. Beside the 
serotonergic deficit in the basal ganglia, cortical areas in the prefrontal cortex such as Brodman 
area9 (BA9), anterior cingulate cortex, entorhinal cortex and hippocampus have lower 5-HT 
levels in PD[324]. This serotonergic deficit is associated with both motor and non-motor 
symptoms in PD as well as the dyskinesia following dopamine enhancement therapy[317, 322]. 
This is consistent with the data from the in vivo 11C-DASB PET study that showed reduction in 
the cortical, brain stem and RN binding of the serotonergic marker in PD[326]. In addition, 
treatment with levodopa favors the conversion of Tryptophan into dopamine instead of 5-HT, 
which further aggravate the preexisting serotonergic dysfunction[322]. 
Although there are contradictory results about SERT expression in PD, SERT reduction 
independent of PD duration, treatment and severity of symptoms is likely[322]. However, 
alterations of SERT in PD depend on the neuroanatomical expression of SERT. The brain 
mapping of SERT pattern in PD is summarized in Figure1.11[324]. 
 
 
Figure 1.11 Alteration of SERT in PD. SERT is reduced in the temporal cortex (dark yellow), 
frontal (light yellow), orbitofrontal (green), visual cortex (light blue), cingulate (dark blue), 
insular cortex, hippocampus and basal ganglia. In depressed PD patients, SERT is increased in 
Prefrontal cortex (orange in A). Reprinted with permission from Elsevier, copyright (2016), from Hout et al. The 
serotonergic system in Parkinson's disease. Progress in Neurobiology. 2011 (95):163-212 . PubMed PMID: 21878363 
 
5-HT1B is expressed in pathways that are relevant to PD such as striatonigral and raphe-
nigral pathways[167]. No compelling evidence indicates modulation of 5-HT1B levels in brain by 
PD pathology alone. The 5-HT1B reductions in orbitofrontal area in PD brains, assessed by 
PET[327], are attributed to physiological reductions due to aging in another report with similar 
methodology[307]. 
  42 
Significant correlation was found between 5-HT1B measured by PET and creativity in 
normal individuals but not PD[328]. However, reports from human studies and animal models of 
PD indicate increased 5-HT1B and p11 in the basal ganglia nuclei[324]. The PET findings of 5-
HT1B, like other receptors, depend on the biochemical characteristics of the ligands, sensitivity 
of the methods, degree of brain atrophy and the type of system model used to evaluate 5-HT1B 
brain expression. For example, no alteration in 5-HT1B striatal expression was found in unilateral 
6-OHDA-lesioned rat, a model of PD[329]. 
Other serotonin receptors such as 5-HT1A and 5-HT2A are also altered by PD 
pathology[324]. This was studied in primates model of PD and human, using PET or binding 
studies. In PD, 5-HT1A is increased in the prefrontal area, the temporal BA36, and in RN[324]. 
Additionally, 5-HT1A agonist is extensively studied in the dopamine-related extrapyramidal side 
effects of neuroleptics medication and dyskinesia[330]. 
1.4.2 Serotonergic system in dementia with lewy bodies (DLB) 
There is an overlap between DLB and PD in different pathological and therapeutic 
aspects[318, 321]. Both neurodegenerative disorders are related to the accumulation of the 
misfolded α-synuclein, inclusion bodies and neuronal degeneration[318]. In addition, both PDD 
and DLB have amyloid and tau pathology. DLB is frequently described as a mixed pathological 
entity between AD and PD[318, 331]. The proportion of DLB among dementias is variable 
between 0-23% depending on the type of the study whether it is a community-based or a clinical 
hospital–based study[318, 321]. 
Definite DLB is a histological diagnosis and the disease is frequently misdiagnosed as AD. 
Presence of particular clinical symptoms such as visual hallucination, extrapyramidal features, 
cognitive fluctuation and visuospatial impairment might help in early differentiation of DLB[332]. 
The frequent symptomatic use of antipsychotics in dementia to alleviate BPSD and the sensitivity 
of DLB patients to antipsychotics in terms of development of side effects require correct 
diagnosis of dementia before commencing neuroleptic medications[333]. 
The 5-HT system has rarely been studied in detail in DLB. Clinical studies showed that DLB 
patients with hallucinations have higher 5-HT turnover in the frontal and temporal cortex 
compared to AD[334]. Moreover, reduction of global cognitive function in DLB has been 
attributed to 5-HT deficit[334, 335]. 
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2 AIMS 
2.1 General aims 
• To investigate the serotonergic and related molecular alterations in cell models of AD. 
• To understand the relationship between serotonergic, pathological and synaptic changes in 
neurodegenerative dementias. 
• To examine platelet serotonin metabolites in AD. 
2.2 Specific aims 
• Paper I : 
To assess alteration in 5-HT1B and related molecules in a familial AD model (APPswe 
mutation). 
• Paper II : 
To characterize the molecular outcomes after pharmacological modulations of the 5-HT 
system in an APPswe-cell model. 
• Paper III : 
To compare the platelets 5-HT metabolites profiles between AD and SCI and correlate 
these to CSF biomarkers and cognition. 
• Paper IV : 
To evaluate expressions of 5-HT1B, 5-HT and 5-HIAA in post-mortem PFC in AD, 
DLB, and PD. 
To study the association of these serotonergic markers with cognition, neuropathology 
and synaptic protein biomarkers of dementia. 
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3 METHODOLOGY 
3.1 Ethical considerations 
All studies in thesis are conducted according to the Helsinki declaration, the local ethical 
review board and Karolinska Institutet guidelines in research with animal and human materials. 
Study I was approved by Stockholm Södra Djurförsöksetiska Nämnd, study III and VI from The 
Regional Ethical Committee in Stockholm (Regionala Etikprövningsnämnden i Stockholm). 
Study II was conducted entirely in an in vitro model, so no ethical permit was required. 
3.2 Materials  
In papers I  and II ,  Taqman gene expression was performed to study gene expression 
profiles of selected 5-HT pathway molecules. We used predesigned assays for 5-HT1B receptor 
gene, SERT (SLC6A4), p11 (S100A10), MAO-A and the housekeeping genes PRLP0 and 
GAPDH were purchased from (Life Technologies, Sweden). For paper I [336], antibodies for 5-
HT1B and S100A10 from (Abcam, Cambridge, UK), and SLC6A4 from (Lifespan Bioscience, 
USA) were used for Western blotting. The enzyme activity kit for MAO-A, MAO- Glo™, was 
purchased from (Promega, USA). 
For paper II [337], we used 5-HT, serotonin creatinine monophosphate from (Sigma, USA), 
the 5-HT1B antagonist (SB224289) and sertraline Hydrochloride (sertraline HCl) from (Tocris, 
UK). We also used the human untagged 5-HT1B cDNA cloned into pCMV6-XL4 vector for the 
in vitro receptor overexpression from (Origene, USA). In addition, we purchased antibodies for 
MAPK pathways with their corresponding positive controls and β-Actin from (Cell signaling, 
USA). For visualization of relative phosphorylations of MAPK pathway we used Proteome 
Profiler™ Array, Human phospho-MAPK array kit was purchased from (R&D systems, UK). 
3.3 Aspects about experimental models we used 
3.3.1 Subjects and clinical assessments 
The study cohort is derived from subjects referred to a university-based memory clinic in 
Karolinska Huddinge hospital in Stockholm. We have selected 2 diagnostic groups of patients: 
An AD group fulfilling the ICD 10 criteria for AD[338] (n=15), and a comparison group with 
normal performance on cognitive tests and normal biomarkers but with memory complaints, i.e. 
subjective cognitive impairment (SCI) (n=20). The diagnostic and evaluation work-up includes 
structured comprehensive clinical, biochemical and imaging workup for the patients as previously 
described[338]. 
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Screening for cognitive function using the Mini-mental state examination (MMSE) and 
neuropsychological assessment were performed[208]. The Cornell Scale for Depression in 
Dementia (CSDD), with the recommended cut-off of 8/9, was used to classify the depression 
severity on the cohort[339, 340] and/or a modified version of the Geriatric Depression Scale 
(GDS) with 20 items, cut-off 5/6[341]. Moreover, patients were interviewed according to 
previous history of depression or use of anti-depressants. Depression was defined as having a 
depression score above the cut-off, a history of depression or the use of antidepressants. In case 
of discrepancy between the scales, CSDD was given priority. 
The clinical evaluation was performed blind to the platelet measurements by a clinician with 
many years of experience in clinical dementia research. Patients with a history of physical 
diseases, which according to the clinician influenced the cognitive functioning, were excluded. 
Participants signed an informed consent. Table 3.1 summarizes the basic characteristic of 
subjects in paper III . 
In paper IV , cognitive data includes the Mini-Mental State Examination (MMSE) data 
(available for 41 of the 57 patients). The majority of patients were longitudinally followed (for 
average 9 years period) and annual rate of decline on MMSE was calculated. The last MMSE 
score was taken maximum two years prior to death. The final diagnoses for patients were made 
according to clinicopathological consensus diagnoses incorporating the 1-year rule to differentiate 
DLB and PDD[342]. The baseline, pathological and clinical characteristics of the study 
population are shown in Table 3.2.  
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Table 3.1 Baseline, laboratory, clinical and medication characteristics of the two study groups 
Characteristic SCI (n=20) 
AD 
(n=15) p-value 
Gender-n (%) 
Female 11 (55.0%) 7 (46.7%) 0.625# 
Age (yr)-median (IQR) 61 (14) 74 (17) 0.006¶ 
MMSE score-median (IQR) 29 (2) 24 (9) <0.001¶ 
Medications-n (%) 
SSRIs 
ASA 
Anticoagulants 
Statins 
Antihypertensive 
Anti-diabetes 
Neuroleptics 
 
3 (15.0%) 
3 (15.0%) 
2 (10.0%) 
5 (25.0%) 
5 (25.0%) 
0 
0 
 
4 (26.7%) 
2 (13.3%) 
0 
2 (13.3%) 
6 (40.0%) 
1 (6.7%) 
0 
 
0.430§ 
1§ 
0.496§ 
0.672§ 
0.344# 
0.429§ 
- 
ApoE ε4-n (%) 
One allele 
 
5 (29.4%) 
 
7 (50.0%) 
 
0.242# 
Depression 
Frequency-n (%) 
 
12 (60.0%) 
 
3 (20.0%) 
 
0.037§ 
CSF Biomarkers-mean (SD) 
Aβ42 
Total tau (T-tau)  
Phosphorylated tau (P-tau) 
T-tau/Aβ42 ratio 
 
1274.0 (280.2) 
250.0 (110.2) 
47.2 (16.7) 
0.19 (0.07) 
 
548.5 (171.0) 
600.1 (309.4) 
79.2 (36.0) 
1.24 (0.80) 
 
<0.001* 
0.001* 
0.009* 
<0.001* 
SCI: subjective cognitive impairment, AD: Alzheimer’s disease, IQR: interquartile range, SD: standard 
deviation, SSRIs: selective serotonin reuptake inhibitors, ASA: acetylsalicylic acid, CSF: cerebrospinal 
fluid 
Shapiro-Wilk test was used to check for the normality of the distribution of numeric variables in each 
study group. Statistical significant differences (two-tailed p-value<0.05) are bolded. 
# Pearson Chi Square statistics 
¶ Mann-Whitney U-test  
§ Fisher’s Exact test 
* Independent Samples T-test 
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Table 3.2 Baseline, pathological and clinical characteristics of the study groups  
Characteristics 
AD  
(n=17) 
DLB  
(n=19) 
PDD  
(n=21) 
All 
Dementia 
(n=57) 
Control  
(n=21) 
p-va lue  
Male sex, n (%) 6 (35.3) 13 (68.4) 9 (42.9) 28 (49.1%) 12 (57.1) 0.182 
Age at death, mean (SD) 87.5 (7.2) 81.5 (7.0) 81.8 (5.0) 83.4 (6.8) 79.7 (7.8) 
0.006 
(AD vs. Control) 
Duration of dementia, mean 
(SD) 
9.7 (2.9) 5.2 (2.7) 2.9 (2.1) 6.5 (4.1) - 
<0.001 
(AD vs. DLB,  
AD vs. PDD) 
Last MMSE score prior to 
death, mean (SD) 
9.2 (7.5) 16.3 (9.3) 15.1 (7.6) 13.6 (8.4) - 0.058 
Rate of annual MMSE 
decline, mean (SD) 
3.9 (3.9) 3.8 (3.8)  1.7 (1.2) 2.8 (3.0) - 0.065 
Braak stage, n (%)       
0 0 0 1 (4.8) 1 (1.8%) 6 (37.5) <0.001 
1/2 0 2 (10.5) 16 (76.2) 18 (31.6%) 8 (50.0) 
(Control vs. DLB, 
AD 
3/4 3 (17.6) 10 (52.6) 3 (14.3) 16 (28.1%) 2 (12.5) PDD vs. DLB, AD 
5/6 14 (82.4) 7 (36.8) 1 (4.8) 22 (30.1%) 0 AD vs. DLB) 
CERAD code, n (%)       
0 (none) 0 5 (26.3) 7 (33.3) 12 (26.7%) 13 (86.7) <0.001 
1 (sparse) 0 7 (36.8) 8 (38.1) 15 (33.3%) 2 (13.3) 
(Control vs. PDD, 
DLB, AD 
2 (moderate) 2 (40.0) 1 (5.3) 2 (9.5) 5 (11.1%) 0 PDD vs. AD 
3 (frequent) 3 (60.0) 6 (31.6) 4 (19.0) 13 (28.9%) 0 AD vs. DLB) 
 
Lewy body score (frontal lobe), 
n (%) 
      
0 (none) 14 (87.5) 11 (61.1) 12 (63.2) 37 (69.8%) 14 (100)  
1 (sparse) 2 (12.5) 1 (5.6) 5 (26.3) 8 (15.1%) 0 0.029* 
2 (moderate) 0 2 (11.1) 1 (5.3) 3 (5.7%) 0  
3 (frequent) 0 4 (22.2) 1 (5.3) 5 (9.4%) 0  
AD: Alzheimer’s disease; DLB: dementia with Lewy bodies; PDD: Parkinson’s disease dementia; SD: standard deviation; n: 
number; MMSE: mini-mental state examination; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease; NIA-
AA: National Institute on Aging-Alzheimer Association; ChEIs: cholinesterase inhibitors. Univariate comparisons have been 
performed using one-way ANOVA or Chi square tests wherever appropriate. Bonferroni post hoc and pair-wise tests were 
used in case of significant p-value of the one-way ANOVA or Chi square tests. All statistical significant differences are 
bolded (p-value<0.05). * None of the pairwise comparisons are statistically significant. 
  
   49 
3.3.2 Human brain 
As previously described[343], brain tissues from patients and normal healthy controls were 
obtained from different centers in UK and Norway; the MRC London Neurodegenerative 
Diseases Brain Bank, the Thomas Willis Brain Collection and the Newcastle Brain Tissue 
Resource, University Hospital Stavanger and stored in the UK brain banks as part of the Brains 
for Dementia Research Network. An informed consent was taken from all participants for their 
tissue to be used in research. This study was ethically approved from The Regional Ethical 
Committee in Stockholm (Regionala Etikprövningsnämnden i Stockholm). Patients were 
diagnosed as AD (n=17), DLB (n=21), or PDD (n=19) during life according to consensus 
criteria[343], and most subjects were followed prospectively as part of longitudinal cohort. 
3.3.3 Platelet fractionation 
Platelets as peripheral model for AD biomarker were used in paper III . Immediately after 
the venipuncture, fractionation of whole blood according to cell density was performed as 
previously described[280]. A total of (7.5 mL) of venous blood was anticoagulated with 2.5 mL 
0.129 M disodium citrate. Fractionation of platelets according to density was performed using 
linear Percoll™ (GE Healthcare Bio-Sciences AB, Sweden) gradient[344-346]. We have chosen 
platelets having particular density in this study as standard, to reduce variability and include a 
homogenous platelets population. Linear Percoll™ gradients covering the density span 1.040 to 
1.090 kg/L were used, particularly plasma–free platelets having a specific density of 1.064 kg/L 
are used from all cases. In addition, the procedure includes a blocking solution to avoid in vitro 
platelet activation and subsequent granule release. Platelet counts were determined electronically. 
Then, the detergent (Triton X-100 final concentration 0.1%) from (Sigma-Aldrich, Missouri, 
U.S.) was used for platelets lysis. Subsequently, cell debris was removed by a short centrifugation 
and samples were stored in -70 until further processing. For internal validation and platelet 
homogeneity determination, the intracellular soluble P-selectin was used as a measure reflecting 
platelet α-granules content, here a commercial immunoassay kit from (R&D Systems, UK) was 
used[345]. 
3.3.4 CSF biomarkers 
We used CSF biomarkers in paper III  as a reference in order to examine the ability of 
peripheral serotonin biomarkers in differentiating SCI from AD. CSF measurements for Aβ42, t-
tau and p-tau were used from memory clinic records at Karolinska Huddinge Hospital, 
Stockholm. The collection and storage of CSF were performed according to local guidelines and 
recommended procedures. The CSF biomarkers tau, p-tau and Aβ42 concentrations were 
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determined with xMAP technology and the INNO-BIA AkzBio3 kit (Innogenetics)[347, 348]. 
The cutoff values for the laboratory to classify normal or abnormal values were: Aβ42>550 ng/l, 
p-tau<80 ng/l and t-tau<400 ng/l. We used the t-tau/Aβ42 ratio as a measure of AD 
pathology[349]. 
3.3.5 Transgenic mice 
For paper I , we used hippocampus from the female Tg2576 mice. These transgenic mice are 
widely used as a genetic animal model of the familial AD mutation (APPswe mutation) in AD 
research since they overexpress the human APP gene with the APPswe double mutation 
(K670N/M671L). At 3 months, they display soluble Aβ aggregates and cognitive dysfunction and 
develop amyloid neurotic plaques after 12 months[350]. Hippocampus samples from different 
age groups were used in this study.  
3.3.6 Cell Culture 
The human neuroblastoma cell line, SH-SY5Y cells (ATCC, USA), were stably transfected 
with the human APP that has the Swedish KM670/671NL double mutation (APPswe) using 
cytomegalovirus promoter-constructed vector as described previously[351]. SH-SY5Y cells with 
the stable transfection of the empty vector p-cDNA 3.1 were used as control cells (Empty vector 
cells).  
Cells were cultured according to the provider’s instruction in MEM (Minimal Eagle Medium) 
(Gibco, life technologies, USA), supplemented with 10% fetal bovine serum. Geneticin, G418 
sulphate, 10µl per ml (life technologies, USA) was used for selection. Cells were grown under 
standard condition of 37°C temperature and 5% CO2 supply. Prior to treatments with chemicals 
of interest, cell medium was replaced with serum-free media and incubated overnight. At 80-90% 
cell confluence, cells were then treated with 5-HT or vehicle alone[352]. The concentrations and 
durations of treatments are shown in Table 3.3 
 
Table 3.3 Experimental Details for paper II 
Substance Company ID or catalogue # Working concentration 
Duration of 
treatment 
5-HT  Sigma Aldrich H7752 10µM 30 minutes 
SB224289  Tocris Bioscience 1221 1µM 2 hours 
Sertraline HCl Tocris Bioscience 1032 10µM 20 minutes 
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3.4 Experimental techniques 
3.4.1 High performance liquid chromatography followed by electrochemical detection 
Concentrations of 5-HT and 5-HIAA in cell culture medium, cell lysate, platelets fractions 
and human brain homogenates were measured using HPLC with electrochemical detection 
previously described[353, 354]. 5-HT and 5-HIAA measurements were conducted separately and 
then 5-HIAA/5-HT ratio was computed as an index for 5-HT turnover and serotonergic activity. 
In summary, for 5-HT measurement we used a HPLC system: HTEC500 (Eicom, Kyoto, Japan), 
and a CMA/200 Refrigerated Microsampler (CMA Microdialysis, Stockholm, Sweden) connected 
with 20µl loop and operating at +4°C. The potential of the glassy carbon-working electrode was 
+450mV vs. the Ag/AgCl reference electrode. The separation was achieved on a 200 x 2.0mm 
Eicompak CAX column (Eicom, Kyoto, Japan). The mobile phase is a mixture of methanol and 
0.1M phosphate buffer (pH6.0) (30:70, v/v) containing 40mM potassium chloride and 0.13mM 
EDTA-2Na[354]. 
A separate HPLC system with electrochemical detection (HTEC500) is used for 
measurement of 5-HIAA concentrations. The potential of the glassy carbon-working electrode 
was +750mV vs. the Ag/AgCl reference electrode. The separation was performed on a 150 x 
3.0mm Eicompak SC-5ODS column (Eicom, Kyoto, Japan). The mobile phase was a mixture of 
methanol and 0.1M citrate and 0.1M sodium acetate buffer solution (pH3.5) (16:84, v/v) 
containing 210mg/L Octanesulfonic acid sodium salt and 5mg/L EDTA-2Na. The 
chromatograms were recorded and integrated by use of the computerized data acquisition system 
Clarity (DataApex, The Czech Republic)[354]. 
3.4.2 Western blotting 
In paper II and I , the Western blot technique is used as a proteomic method for semi-
quantitatively compare certain makers across different experimental groups. The method was 
performed as described before[336, 355]. 
Briefly, proteins from cells or mice hippocampus tissues were extracted using a standardized 
lysis buffer supplemented with anti-protease and anti-phosphatase cocktail (Sigma Aldrich, MO). 
Samples were then centrifuged to 13000 rpm for 15 minutes. The supernatant (the extracted 
protein) was transferred to clean 1.5 ml polypropylene tube and stored at -20° C until use. The 
determination of the total protein concentration was done with BCA kit (Pierce, Rockford, IL, 
USA). The supernatant was mixed with NuPAGE® LDS sample buffer (4X) (Life technologies) 
and heated to 100° C for 5 minutes and loaded on 10% acrylamide SDS-PAGE gels for protein 
separation. An overnight transfer to a nitrocellulose membrane (0.2 µm pore size membrane 
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Protran® (BA83, Whatman, GE Healthcare)) was done at 4°C. Membranes were then blocked 
with 5% milk (BCR685 FLUKA, Sigma Aldrich) for 1 hour. The different primary antibodies 
(diluted in TBS-Tween buffer) used for paper 1  are shown in Table 3.2. For paper II ,  primary 
antibodies for p70S6, phospho-p70S6 (Thr389), phospho-p70S6- (Thr421, Ser424), p70S6 and 
pMAPK (42-44), total MAPK[352] from Cell signaling, USA were used. 
Each experiment was done 3 times in separate biological material. In cell culture experiments 
we used the same cell culture passage to control for variability between passages and for each 
experiment n=6. Table 3.4 shows details about some antibodies used in paper I  and II .  
 
Table 3.4 Primary antibodies used for Western blotting 
The Antigen Company Cat # Dilution Species  
5-HT1B Abcam ab13896 1:500 Rabbit 
S100A10 (p11) Abcam ab76472 1:5000 Rabbit 
SLC6A4 (SERT) Life Span Bioscience, Inc, LS-C156102 1:1000 Rabbit 
GAPDH Enzo ADI-CSA-335-E 1:5000 Mouse 
3.4.3 Gene expression analysis 
Total RNA from SHSY5 cell cultures and Tg2576 mice hippocampus tissues were isolated 
using the RNeasy mini kit (Qiagen, USA) after DNAse treatment (RNase-Free DNase Set, 
Qiagen, USA). Subsequently, extracted RNAs were separated on agarose gels to exclude genomic 
DNA contamination and ensure the integrity of extract RNA. 
This is further followed by reverse transcribed using High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, USA). For the amplification reaction analysis, we used 
Relative Standard Method supplied by Applied Biosystem[356]. A set of relative standard curves 
from human and mice samples were created and the relative quantities were measured and 
compared across the plates by plotting the threshold cycle (Ct) of each sample with that of the 
standard curve run in the same PCR plate. Different series of real-time PCR reactions were 
determined to quantify the both target genes and endogenous control sequences (glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) or ribosomal protein lateral stalk subunit P0 (PRLP0) or 
both). 
Thermo-cycling and fluorescence detection was performed according to TaqMan®Gene 
Expression Assays Protocol using ABI PRISM® 7000 Sequence Detection System. PCR Master 
Mix (Applied Biosystems), and TaqMan® Gene Expression Assays (Applied Biosystems) were 
used in the amplification reaction. The stability of endogenous control, GAPDH and RPLPO, 
was measure by determining RNA copy numbers and estimating normalization factor (NF). This 
was performed using the software GeNorm 3.3 visual basic application for Microsoft Excel 
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(http://medgen.ugent.be/∼jvdesomp/genorm/)[356]. Finally, mRNA copy numbers of all target 
transcripts were adjusted by a normalization factor (NF). 
3.4.4 MAO-A enzyme activity 
MAO-A activity was determined using MAO-Glo™ kit (Promega, USA)[357]. Adding equal 
volumes of 4X prepare the reactions MAO substrate preparations to of 4Xtest preparation to 
initiate a luciferase reaction. Then, 25 μl of MAO-A was added to each reaction. Two different 
types of negative controls were used; either 25 microliters of MAO-A enzyme or 12.5 microliter 
of test preparation were added. After incubation for 1 hour at room temperature, stabilized 
luminescence signals were obtained when of luciferase detection solution was added and 
incubated again at room temperature for 20 minutes. 
Luminescence was measured at an integration time of one second per well in a plate reader 
(Tecan Safire II). Relative light units (RLUs), expression for MAO-A activity, were calculated by 
subtracting values from negative controls without MAO-A enzyme from test preparations[352]. 
3.4.5 MAPK protein arrays 
The Proteome Profiler™ Array, Human phospho-MAPK array kit (R&D systems, UK), to 
determine the relative phosphorylation of more than 20 members of the human MAPK[352, 
358]. First, membranes were blocked with array buffer; this is followed by addition of 150 
micrograms of protein. The membranes together with the antibody detection cocktail are 
incubated overnight at 4◦C. The membranes were then washed incubated in streptavidin HRP, 
diluted in buffer 5, for 30 min. Membranes were washed again and final brief wash is carried out 
three times. Blot images were visualized with CCD camera. 
3.4.6 ELISA  
To quantify levels of 5-HT1B in brain homogenate in Paper IV , we used the human 5-
HT1B receptor ELISA kit from EIAab®, China and according to the manufacturer’s 
instructions. We extracted data of the synaptic proteins Rab3A, SNAP25 and neurogranin from 
previously published report[359]. Beside ELISA, Aβ42, Aβ40, tau, p-tau and α-synuclein were 
measured by IHC as described before[360]. 
3.5 Statistical analysis 
All statistical analyses were performed using SPSS software, version 22 (Armonk, NY: IBM 
Corp.). For paper I  and paper II ; the data was assessed for normal distribution by Kolmogorov-
Smirnov test. For comparison of two groups T-test or Mann-Whitney test was used. Similarly, 
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one-way ANOVA or Kruskall Wallis test followed by post hoc Tukey’s or Dunn’s tests were 
used for multiple group analysis. Level of significance is taken at p-value of ≤0.05 was. Data are 
either expressed as mean ± SEM or as median ± interquartile range (IQR) in addition to plots 
showing the distribution according to normality of data[361]. 
For paper III , the concentrations of 5-HT and 5-HIAA were adjusted to the fraction’s 
protein concentration and fraction’s platelet count. For description of normality of distribution 
or skewness of the data, mean and standard deviation (SD) or median and interquartile range 
(IQR) were used respectively. Like statistical analysis in paper I  and II ,  Shapiro-Walk test was 
used to examine the normality of distribution for numeric variables. The unadjusted univariate 
comparisons between SCI and AD groups were evaluated using independent samples T-test, 
Mann-Whitney U-test, Pearson Chi square and Fisher’s exact tests were used for numeric, 
ordinal, and nominal variables wherever appropriate. As the main analysis, we applied 
multivariate ordinal logistic regression to adjust for differences in tertiles of platelets serotonin 
indicators between SCI and AD groups for participants’ age, depression status (yes/no), and P-
selectin level. Adjusted odds ratio (OR) and their 95% confidence interval (CI) were reported for 
each regression model. Correlations were performed using Spearman test, and adjusted for age 
using partial correlation. Based on the inspection of the data, the SCI group was divided into two 
subgroups based on the median value of the protein-corrected 5-HT level. Mann-Whitney U test 
and linear regression model were used to compare the CSF biomarkers between the SCI with 
high 5-HT and low 5-HT. A p-value of <0.05 was considered statistically significant. 
For  paper IV , Continuous numeric and categorical variables are described using mean 
(standard deviation (SD)), median (interquartile range (IQR)) and frequency (percentage), 
respectively. For univariate between-group comparisons, we used Kruskal-Wallis, one-way 
ANOVA or Chi square wherever appropriate. Bivariate correlations between different 
continuous measurements have been assessed by means of Spearman non-parametric test due to 
the skewed distribution of numeric variables. 
The multivariate analyses was performed using either linear (for numeric values of 
biomarkers and rate of decline in MMSE as the outcome) or ordinal logistic (for tertiles of 
biomarkers’ concentration as the outcome) regression models adjusted for age at death and sex 
where control group has been defined as the reference condition. A two-tailed p-value of <0.05 
indicated statistically significant differences or associations. A number of comparisons were made 
without attempts to adjust, and thus findings need to be interpreted with caution and need 
replication in larger studies. 
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4 RESULTS AND DISSCUSSION 
 
This chapter summarizes the main results of the thesis and their implications in the context 
of relevant literature; the rest of the results and a more comprehensive discussion can be viewed 
in the individual papers. 
4.1 Aspects of 5-HT1B in Alzheimer’s disease 
4.1.1 5-HT1B expression in Alzheimer’s disease models 
 
Few reports about 5-HT1B in AD were available prior to my work, and to our knowledge, 
we have the first report discussing 5-HT1B expression in familial AD models (APPswe).  
 
 Reduction in the binding of 5-HT1B in the frontal and temporal cortex of sporadic AD was 
reported in postmortem study in human[286]. The levels of 5-HT1B in other AD brain areas, 
transgenic animal and cell models of AD still remain unknown. Based on that and the unknown 
functional implications of 5-HT1B in dementia, 5-HT1B has a lot of novelty aspects in this 
paradigm. 
 
In paper I , we have studied the expression of 5-HT1B in both in vitro and ex vivo model of 
AD. We used SH-SY5Y neuroblastoma cell line that stably transfected with the familial mutation 
APP Swedish (APPswe) together with hippocampus homogenate from the transgenic mice 
Tg2576 that overexpress APPswe[361]. In addition, we studied the postmortem levels of 5-HT1B 
levels in the PFC (BA9) in a mixed dementia cohort with AD, PDD, DLB and healthy subjects in 
Paper IV .  
 
SH-SH5Ycell line is a neuronal cell line that has a moderate expression of 5-HT1B, while the 
hippocampus represents one of the most abundant brain areas in 5-HT1B. In paper I , our results 
suggested reduction of 5-HT1B protein and mRNA in APPswe cells (Figure 4.1) and reduction 
of the hippocampal 5-HT1B in Tg2576 mice (Figure 4.2)[361]. Tg2576 mice are acceptable 
model of AD. Although they develop the behavioral symptoms of cognitive impairment after 6 
months, obvious biochemical characteristics of AD are seen at about one year of age. These 
biochemical changes include amyloid plaques, excessive inflammation, significant oxidative stress, 
tauopathy and synaptic degeneration[362]. 
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Figure 4.1 Comparison between APPswe cells and control cells in the levels of selected serotonin 
markers. A. Western blot bands for 5-HT1B in APPswe and control cells (Empty vector). B, C and D 
are relative quantification of 5-HT1B, p11 and SERT respectively. E. Shows gene expression of APP in 
control cells and APPswe cells. Data is expressed as SEM, n=3-4. (*p<0.05, **p<0.01 and ***p<0.001) 
Reprinted with permission from Elsevier, copyright (2016). 
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Figure 4.2. Expressions of 5-HT1B (A, B and C) and SERT (A, B and D) in hippocampus of 
female Tg2576 mice in different age groups. Data is expressed as SEM, n=3-4. (*p<0.05, **p<0.01 
and ***p<0.001). Tg: Tg2576. WT: wild type mice. Reprinted with permission from Elsevier, copyright (2016). 
 
The physiological factors related to 5-HT regulation and subsequent effects on cognition 
might determine the expression of 5-HT1B in dementia. 5-HT1B is not only a negative regulator 
of 5-HT and acetylcholine release under physiological conditions but also is relevant to 5-HT and 
cholinergic deficit in AD[296]. Furthermore, the use of selective 5-HT1B agonists leads to 
negative outcomes in memory compared to the selective antagonists. Together, these indicate 
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that increased activity of 5-HT1B is related to memory impairment[137]. Reduction of 5-HT1B 
levels in AD might be attributed to the neuronal loss during the neurodegenerative process. 
Alternatively, it could be due to compensatory mechanisms to reinforce acetylcholine and 
serotonin levels by releasing the inhibitory tone of 5-HT1B by decreasing its expression[286]. 
There are some limitations in our cell and mice models used in paper I . For the in vitro 
model, we used control cells in form of SH-SY5Y cells transfected with the empty vector, which 
are acceptable control. While the most suitable control to show the exact effect of a mutated 
APPswe gene is cells transfected with the APP gene without APPswe mutation (APP wild type). 
In addition, in the mice experiment in paper I ,  we did not provide identical age groups in 
Tg2576 and the control group. We included age groups 6 months and 2 years in the wild type 
mice, while additional 9-month-old and 12-month-old age groups were included in Tg2576 mice. 
Another limitation is that we used female only Tg2576 mice and this is due to a technical 
difficulty in including the male Tg2576 mice. The reason for using female, as in most other 
studies as well, is that one cannot have male mice together since they will fight and may end up 
killing each other. The alternative would be to keep them in separate cages and that causes stress, 
since they do not live alone in their natural habitat. Still, using only female mice might raise issues 
regarding the sex-hormones effects on 5-HT system, particularly the effect of estrus cycle on 
brain metabolism. For example comparing 6-month-old to 12-month-old group mice is a 
comparison of two different phases in the reproductive life, with two different sex-hormones 
profiles. 
It is important to note that loss of 5-HT1A binding has already been reported in two 
transgenic mice models of AD[41]. Therefore, the changes in 5-HT transmission in AD cannot 
be explained entirely by modulation in expression and activity of 5-HT1B alone. 
Treating APPswe cells with exogenous Aβ42 peptide produced no effect on 5-HT1B protein 
levels in control cells (result not shown here). Of note, the mechanism of 5-HT1B alterations is 
unknown and not investigated thoroughly in this thesis.  
Aging affects the expression of 5-HT1B in brain. After twenty years of age, a gradual 
decrease of 5-HT1B binding potential by about 10% for each decade of life, in all human brain 
regions, was shown[307]. These findings are in line with results from animal models that showed 
reduction of 5-HT1B mRNA in forebrain areas, striatum, piriform cortex and septum but not in 
RN in 2-year-old rats compared to 4-month-old[363]. Importantly, reduction of 5-HT1B in brain 
is associated with the early onset of age-related dysfunctions. Premature age-related motor 
dysfunction, decreased survival and increased gene expression of age-related markers are 
demonstrated in 5-HT1BKO mice[364]. The densities of 5-HT1B, measured by the binding of 
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the 5-HT1B/1D antagonist ([3H]-GR-125743), are reduced in temporal and frontal cortical areas 
in sporadic AD[286]. This study reported more reduction of 5-HT1B density in the temporal 
cortex (BA20) (37% reduction) compared to 25% reduction in the frontal brain area (BA10)[286]. 
To assess the pattern of 5-HT1B in different dementia sub-groups and relate this to the 
pathological markers of dementia, we used data derived from a cohort consist of three 
neurodegenerative diseases (AD, DLB, PDD) and a control group. The demographic factors and 
dementia neuropathological staging for this cohort are shown in Table 3.2. 
Data for the pathological profiles for amyloid protein, tau and α-synuclein as well as selected 
synaptic proteins are used. In paper IV , pathological and synaptic biomarkers data was extracted 
from data published before for the same cohort[359, 365]. Our objective in this study is to 
investigate 5-HT1B levels in PFC (BA9 brain area) in dementia and to study their relation to 
pathological and synaptic markers. As shown in Table 4.1, we found that all the dementia groups 
have higher levels of 5-HT1B in BA9 brain area than the age and sex-matched control group. 
Significant difference was observed in the AD group (p=0.012). 
In contrast to previous studies in AD, no available data indicates the downregulation of 5-
HT1B in the PFC in PDD or DLB. PET studies suggested age-related changes of 5-HT1B in the 
brain stem and limbic system in PD, still no changes is detected in any of the cortical areas[327]. 
Levels of 5-HT1B could be affected by dopaminergic treatment in PD, particularly in the 
striatum-related neuronal projections[329]. In our cohort 90% of the PD subjects were covered 
by anti-Parkinson’s medications. This might influence 5-HT1B levels despite the difference in the 
brain areas studied between our study and the previous report. Both depression and its treatment 
are associated with 5-HT1B and the adaptor protein p11[153]. Furthermore, another limitation to 
this study is that 5-HT1B levels were not adjusted for the depression scores. Therefore, changes 
in 5-HT1B levels could be attributed to depression in this study cannot be excluded. The study 
also lacks correction of the data to the antidepressant usage, educational assessment for 
participants, their ethnic backgrounds and past medical health conditions data. The adaptor 
protein (p11) impacts not only the depression phenotype, but also the response to antidepressant 
and the antidepressant-related 5-HT1B alterations[153]. When we divided the dementia sub-
groups into tertiles according to their 5-HT1B concentrations, 52.9% of AD and 47.4% of DLB 
subjects were in the 3rd tertile with the highest 5-HT1B levels, compared to only 14.3% in the 
control group. Results for 5-HT1B in BA9 are shown in Table 4.1. 
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The associations between 5-HT1B levels and the annual rate of MMSE decline or last 
MMSE prior to death are shown in Table 4.2 and Table 4.3.  
Our multivariate regression model in Table 4.2 indicates that subjects in the highest tertile 
of 5-HT1B in BA9 from AD, PDD and combined dementias groups have greater decline of 
MMSE compared to the subjects belong to the first tertile of 5-HT1B (lowest 5-HT1B or 
reference group). Despite alterations of 5-HT1B levels in BA9 in DLB, association between 5-
HT1B and rate of MMSE decline is insignificant in this group. In addition, no associations 
between 5-HT or 5-HIAA and the rate of MMSE in BA9 were observed (Table 4.2). 
As shown in Table 4.3, when we replaced the rate of MMSE decline by the MMSE score 
prior to death in the model, no similar results were found. Of note, being in the 2nd tertile of the 
5-HT1B in the AD group is associated with an average of -8.3 lower last MMSE score compared 
to those AD patients in the 1st tertile of the 5-HT1B. In contrast to 5-HIAA in AD, higher 5-HT 
levels in PDD are associated with lower MMSE scores prior to death. 
Unexpectedly, no associations between 5-HT1B and 5-HT, 5-HIAA or 5-HIAA/5-HT ratio 
were observed in any of the diagnostic groups (results not shown). 
 
Table 4.2 Multivariate regression model to investigate the association between rate of MMSE decline and 
concentration of serotonergic biomarkers in the prefrontal brain BA9 area in patients with AD, DLB and PDD 
Measurement Group 
Regression coefficient (95% CI) 
1st tertile  2nd tertile  3rd tertile  
HT1B 
AD Reference 3.58 (-1.28 – 8.43), p=0.149 4.66 (1.22 – 8.10), p=0.008 
DLB Reference -0.69 (-6.38 – 5.01), p=0.813 -1.45 (-6.56 – 3.67), p=0.580 
PDD Reference 0.53 (-0.31 – 1.37), p=0.214 1.23 (0.18 – 2.28), p=0.022 
All (n=41) Reference 0.79 (-1.33 – 2.92), p=0.464 2.49 (0.44 – 4.54), p=0.017 
5-HT 
AD Reference -0.15 (-6.12 – 5.82), p=0.962 -2.15 (-8.92 – 4.62), p=0.534 
DLB Reference 14.99 (-1.70 – 31.67), p=0.078 -9.15 (-18.46 – 0.16), p=0.054 
PDD Reference 0.17 (-0.95 – 1.28), p=0.768 0.55 (-0.43 – 1.53), p=0.271 
All (n=35) Reference 2.01 (-0.43 – 4.45), p=0.106 -0.76 (-3.35 – 1.82), p=0.563 
5-HIAA 
AD Reference -3.84 (-8.33 – 0.65), p=0.093 -6.09 (-12.33 – 0.15), p=0.056 
DLB Reference 0.36 (-4.25 – 4.97), p=0.879 -* 
PDD Reference 0.44 (-0.56 – 1.44), p=0.391 0.30 (-0.81 – 1.41), p= 0.595 
All (n=35) Reference 0.17 (-2.16 – 2.51), p=0.886 -1.19 (-4.23 – 1.85), p=0.441 
5-HIAA/5-HT 
AD Reference 0.13 (-7.08 – 7.34), p=0.972 -2.00 (-7.39 – 3.39), p=0.467 
DLB Reference -0.36 (-4.65 – 3.92), p=0.868 -4.28 (-9.51 – 0.95), p=0.109 
PDD Reference -0.12 (-1.27 – 1.03), p=0.839 -0.08 (-1.08 – 0.92), p=0.873 
All (n=35) Reference -0.05 (-2.62 – 2.52), p=0.972 -1.31 (-3.84 – 1.23), p=0.314 
Regarding availability of data for MMSE and the biomarkers, there are some missing cases for each regression 
model. Number of valid cases included in each model is mentioned in parentheses. 
All regression models have been adjusted for age at death and sex. All statistical significant coefficients are bolded 
(p-value<0.05). CI: confidence interval. * There are only two patients with the 3rd tertile of 5-HIAA 
concentrations in the DLB group and the model could not calculate regression coefficient. 
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Table 4.3 Multivariate regression model to investigate the association between the last MMSE score before death 
and concentration of serotonergic biomarkers in the prefrontal brain BA9 area in patients with AD, DLB and PDD  
Measurement Group 
Regression coefficient (95% CI) 
1st tertile  2nd tertile  3rd tertile  
HT1B 
AD Reference -8.3 (-15.2 – -1.5), p=0.018 -2.0 (-6.9 – 2.8), p=0.418 
DLB Reference 5.9 (-7.0 – 18.9), p=0.368 3.3 (-7.2 – 13.8), p=0.537 
PDD Reference 0.1 (-6.1 – 6.3), p=0.980 -6.3 (-14.1 – 1.5), p=0.111 
All (n=45) Reference -0.1 (-5.6 – 5.5), p=0.983 -3.5 (-8.6 – 1.6), p=0.183 
5-HT 
AD Reference 8.1 (1.7 – 14.5), p=0.013 5.4 (-1.4 – 12.2), p=0.123 
DLB Reference -8.7 (-18.3 – 0.0), p=0.076 6.5 (-3.7 – 16.8), p=0.211 
PDD Reference -4.5 (-12.1 – 3.0), p=0.240 -7.0 (-13.6 – -0.3), p=0.040 
All (n=39) Reference -4.5 (-10.5 – 1.5), p=0.138 -0.6 (-7.0 – 5.7), p=0.845 
5-HIAA 
AD Reference 3.4 (-2.1 – 8.9), p=0.227 9.4 (1.7 – 17.1), p=0.017 
DLB Reference -9.8 (-18.1 – -1.5), p=0.021 -* 
PDD Reference -2.4 (-9.5 – 4.8), p=0.518 -5.5 (-13.4 – 2.5), p=0.178 
All (n=39) Reference -3.3 (-8.9 – 2.3), p=0.244 -0.3 (-8.0 – 7.4), p=0.938 
5-HIAA/5-HT 
AD Reference 1.6 (-7.3 – 10.4), p=0.727 2.2 (-5.0 – 9.4), p=0.550 
DLB Reference -0.9 (-10.9 – 9.0), p=0.854 0.9 (-14.8 – 16.6), p=0.914 
PDD Reference 2.1 (-6.3 – 10.6), p=0.620 -0.3 (-7.6 – 7.0), p=0.939 
All (n=39) Reference 1.9 (-4.0 – 7.7), p=0.534 1.4 (-5.1 – 7.9), p=0.676 
Regarding availability of data for MMSE and the biomarkers, there are some missing cases for each regression 
model. Number of valid cases included in each model is mentioned in parentheses. 
All regression models have been adjusted for age at death and sex. All statistical significant coefficients are bolded 
(p-value<0.05). CI: confidence interval. * There are only two patients with the 3rd tertile of 5-HIAA concentrations 
in the DLB group and the model could not calculate regression coefficient. 
 
4.1.2 Associations between 5-HT1B, synaptic and pathological markers 
We used a multivariate analysis adjusted for age at death and sex to investigate the 
association between 5-HT1B and synaptic markers in BA9. As shown in Table 4.4, four 
diagnostic groups (AD, DLB, PDD and control) and different pathological and synaptic 
biomarkers are included in this model.  
No correlation was found in any of the dementia groups, between Aβ42, Aβ40 or the Aβ42/ 
Aβ40 ratio and 5-HT1B. Conversely, in the control group we found significant positive 
correlation between 5-HT1B and the amyloid based-biomarker Aβ42, Aβ40 and the Aβ42/Aβ40 
ratio (p=0.001, 0.017 and 0.017 respectively, (data not shown). However, no association between 
5-HT1B and tau, α-synuclein or any of the synaptic markers was seen in the control group. 
Significant positive correlation between 5-HT1B and α-synuclein was observed in DLB (adjusted 
correlation coefficient = 0.73, p=0.01), see Table 4.4.  
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Table 4.4 Multivariate correlation between serotonergic, synaptic, and proteinopathy 
Variables AD (n=17) DLB (n=19) PDD (n=21) 
α-synuclein    
5-HT1B 0.32 (0.346) 0.73 (0.010) 0.02 (0.952) 
5-HT -0.15 (0.651) 0.36 (0.274) -0.40 (0.141) 
5-HIAA 0.10 (0.763) 0.03 (0.930) -0.25 (0.365) 
5-HIAA/5-HT 0.26 (0.438) -0.19 (0.580) 0.17 (0.552) 
Aβ42    
5-HT1B 0.32 (0.308) -0.08 (0.774) 0.14 (0.594) 
5-HT -0.34 (0.283) -0.06 (0.829) -0.02 (0.929) 
5-HIAA -0.41 (0.191) -0.05 (0.854) -0.06 (0.802) 
5-HIAA/5-HT -0.06 (0.862) 0.03 (0.928) -0.08 (0.763) 
Aβ40    
5-HT1B -0.05 (0.875) 0.19 (0.472) 0.04 (0.873) 
5-HT -0.52 (0.085) -0.27 (0.310) 0.05 (0.855) 
5-HIAA -0.17 (0.589) 0.18 (0.498) -0.08 (0.755) 
5-HIAA/5-HT 0.54 (0.071) 0.39 (0.131) -0.11 (0.664) 
T-tau    
5-HT1B 0.04 (0.891) -0.22 (0.415) -0.05 (0.856) 
5-HT -0.12 (0.710) 0.34 (0.195) 0.24 (0.329) 
5-HIAA -0.18 (0.564) 0.07 (0.795) 0.19 (0.458) 
5-HIAA/5-HT -0.14 (0.668) -0.17 (0.523) 0.04 (0.880) 
P-tau    
5-HT1B -0.29 (0.360) 0.12 (0.648) 0.13 (0.600) 
5-HT -0.40 (0.204) -0.12 (0.658) -0.33 (0.179) 
5-HIAA -0.17 (0.603) 0.08 (0.760)  -0.39 (0.106) 
5-HIAA/5-HT 0.20 (0.536) 0.13 (0.627) -0.40 (0.096) 
Rab3A    
5-HT1B -0.28 (0.358) -0.21 (0.427) -0.04 (0.863) 
5-HT 0.12 (0.700) -0.48 (0.063) 0 (1) 
5-HIAA -0.29 (0.339) 0.15 (0.588) 0.02 (0.937) 
5-HIAA/5-HT -0.59 (0.034) 0.38 (0.147) 0.09 (0.728) 
SNAP25    
5-HT1B -0.39 (0.182) -0.61 (0.012) -0.11 (0.670) 
5-HT -0.40 (0.174) 0.13 (0.645) 0.37 (0.135) 
5-HIAA -0.08 (0.805) -049 (0.052) 0.42 (0.085) 
5-HIAA/5-HT 0.13 (0.684) -0.58 (0.018) -0.02 (0.932) 
Neurogranin    
5-HT1B -0.16 (0.611) -0.19 (0.471) 0.23 (0.357) 
5-HT  0.30 (0.312) -0.59 (0.016) -0.21 (0.397) 
5-HIAA  0.35 (0.247) 0.42 (0.106) -0.43 (0.073) 
5-HIAA/5-HT -0.01 (0.970) 0.70 (0.002) -0.57 (0.014) 
Regarding the number of valid data for each biomarker, there are some missing cases for each 
of the correlations ranging from n=1 to n=4. AD: Alzheimer’s disease; DLB: dementia with 
Lewy bodies; PDD: Parkinson’s disease dementia; Aβ: amyloid-beta; P-tau: phosphorylated tau; 
T-tau: total tau. All multivariate correlations have been performed using partial correlation 
adjusting for age at death. Data are presented as adjusted. 
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Particular synaptic proteins such as the postsynaptic protein neurogranin, the synaptosomal-
associated protein 25 (SNAP25) and the presynaptic protein Rab3A are associated with cognitive 
decline and dementia neuropathology[359]. 
In this study, we used previously published quantitative proteomic data for selected synaptic 
proteins[359] to test the hypothesis that these proteins correlate with serotonergic markers in 
dementia. The data suggests not only expression modulation but also the potential of 
neurogranin, SNAP25 and Rab3A in detecting cognitive decline in AD, PDD and DLB[359]. 
The multivariate analysis, partially adjusted to age of death, indicates an inverse correlation 
between 5-HT1B and SNAP25 in DLB (adjusted correlation coefficient=-0.61, p=0.012). In the 
DLB group again, negative correlations were observed between 5-HIAA and SNAP25 (adjusted 
correlation coefficient=-0.49, p=0.052), and the 5-HIAA/5-HT ratio and SNAP25 (adjusted 
correlation coefficient=-0.58, p=0.018). In addition, another inverse correlation was observed 
between 5-HT and neurogranin (adjusted correlation coefficient=-0.59, p=0.016) in DLB. 
A positive correlation was also noticed between the 5-HIAA/5-HT ratio and neurogranin 
(adjusted correlation coefficient=-0.70, p=0.002) in DLB. 
In PDD, a negative correlation was observed between the 5-HIAA/5-HT ratio and 
neurogranin (adjusted correlation coefficient=-0.57, p=0.014). However, no association was 
found between serotonergic markers and any of the selected synaptic proteins in AD group 
(Table 4.4). 
In contrast to AD and PDD, our results suggest that the pathological marker α-synuclein is 
associated with the prefrontal expression of 5-HT1B in DLB group. Provided that DLB is a 
disorder of mixed α-synuclein and amyloid pathology, this suggests their integrated effect on 5-
HT1B brain expression. 
The predominant negative correlations between SNAP25 and serotonergic markers might 
indicate a compensatory synaptic activity to 5-HT deficit in DLB. Moreover, the relationship 
between serotonergic markers and synaptic proteins cannot be described by a unified trend. For 
instance, SNAP25 is associated with decreased serotonergic activity (5-HIAA/5-HT ratio) in 
contrary to neurogranin.  
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4.2 Modulations of the serotonergic system in Alzheimer’s disease 
4.2.1 Modulations of SERT 
Depression is common and relevant to dementia and can present as prodromal symptom or 
symptom during the course of full-blown dementia[319]. Despite the previous knowledge about 
the positive effect of SSRIs on cognitive function and brain 5-HT levels, recent reports indicate 
that antidepressant, such the SSRI sertraline has no clinical effect on depression in AD[236]. 
Moreover, multiple reports demonstrated the downregulation of SERT expression in AD shown 
in different brain areas[41, 361]. 
We treated APPswe cells with sertraline to compare the serotonergic outcomes between in 
vitro AD model and control cells (Figure 4.3). First, we checked SERT gene expression in both 
types of cells after sertraline HCl treatment to exclude that changes in outcomes after sertraline 
treatment are due to modulation of SERT gene expression (Figure 4.3 B). No significant 
difference in SERT gene expression was observed in any of the experimental groups after 
sertraline treatment. 
There is an increase in 5-HT1B gene expression in APPswe following sertraline HCl 
treatment compared to control cells, which is independent of the basal 5-HT1B and SERT gene 
expression differences between APPswe and control cells (Figure 4.3 A). 
We further measured 5-HT, 5-HIAA and calculated the serotonin turnover index 5-
HIAA/5-HT both in the cell lysate and cells’ medium to determine the intra and extracellular 
effects of sertraline on 5-HT metabolites (Figure 4.4). Importantly, sertraline decreased 
intracellular 5-HT levels in APPswe (Figure 4.4 B). Although higher levels of intracellular 5-
HIAA were observed in both APPswe and control cells after sertraline treatment (Figure 4.4 D), 
a significant difference in the intracellular 5-HIAA/5-HT ratio was observed in APPswe cells but 
not control cells (Figure 4.4 F). No changes in 5-HT and 5-HIAA levels, measured in the cell 
medium or 5-HIAA/5-HT ratio, were noted after sertraline treatment in APPwe or control cells 
(Figure 4.4 G-L). 
Because of the lack of effect on extracellular 5-HT metabolites, this data indicates acute 
inhibition of intracellular 5-HT and stimulation of 5-HIAA productions by sertraline in APPswe 
in a SERT-independent mechanism. Animal infusions and human functional imaging studies are 
needed to confirm and elaborate on these initial findings. The role of sertraline-dependent 
modulation in 5-HT1B expression and function in AD can be speculated as a contributing factor 
to these changes (Figure 4.3 A). Our findings show that lower MAO-A activities in APPswe 
cells treated with sertraline, which also indicate that these changes are MAO-A-independent 
modulations (Figure 4.5).   
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Figure 4.3 Gene expression profiles in APPswe after pharmacological modulations. A and D; 5-
HT1B gene expression. B and C; SERT gene expression. E; p11 gene expression. Experimental 
conditions are shown in Table 3.3 
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Figure 4.4 Intracellular (A-F) and extracellular (G-L) 5-HT and 5-HIAA measured after sertraline 
treatment and the 5-HT1B antagonist (SB224289) in APPswe and Empty vector (control cells). 
Experimental conditions are described in Table 3.3. 
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Figure 4.5 Comparison between Basal MAOA-A gene expression (A) and activity in APPswe and 
Empty vector (control cells).  
 
 The interaction between 5-HT1B and SERT in the regulation of 5-HT transmission was 
discussed before[58]. SB224289 inhibits SERT function in mice and this could explain the 
compensatory increase in SERT gene expression after SB224289 treatment[58]. In addition, 
normal 5-HT1B expression and function are necessary for the SERT-mediated 5-HT uptake 
(Figure 1.2). The high upregulation of SERT gene expression, after blockade of 5-HT1B by 
SB224289 in AD models, could be partially due to abnormal function and expression of this 
receptor in AD. 
Of note, the interactions between SERT and 5-HT1B, at the genetic and functional levels, 
could modify the inhibitory tone of 5-HT1A and thus add further influence on 5-HT release[58, 
366]. 5-HT transmission can be affected by particular SERT genetic polymorphisms. However, 
no convincing data suggests higher prevalence of particular SERT polymorphisms in AD[314]. 
Moreover, SERT and 5-HT1B interactions in AD are not studied yet. 
Increased adverse side effects and lack of benefits in treating depression in AD were shown 
in antidepressants particularly sertraline and mirtazapine in a randomized, multicenter, double 
blind, placebo-controlled trial[236]. We suggest that the refractoriness of SSRIs in AD could be 
due to SSRI-induced molecular events in AD that might, early, activate or increase expression of 
5-HT inhibitory receptors such as 5-HT1B and 5-HT1A instead of the desired desensitization of 
these receptors[155]. Consequently, activation of these receptors would results in lower 
intracellular 5-HT levels and subsequent decrease in the release of 5-HT in longer time scales. 
On other hand, 5-HT1B reduces 5-HT clearance in hippocampus and the blockade of 5-
HT1B by the selective antagonist SB224288 produces more inhibition of 5-HT clearance than the 
SSRI fluvoxamine[367]. However, this reuptake inhibition of SB224289 is dependent on the 
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integrity of 5-HT1B, which is still not studied in AD. The blockade of 5-HT1B is a potential 
adjunct to SSRIs for 5-HT reuptake modifications[368]. Although SB224289 showed increased 5-
HT levels of 5-HT both in vivo and in vitro by the selective blockade of 5-HT1B[369], our results 
showed no effect of this compound in APPswe or control cells in modulating 5-HT metabolites 
levels. This could be due to the type of cell model or the experimental conditions we used. 
One limitation of this study is that it didn’t show the detailed mechanism of elevation of 5-
HT1B mRNA following sertraline HCl treatments in APPswe cells. Although the validation 
experiments and previous data from the cell line we used have demonstrated higher levels of 
amyloid species in APPswe, a modification of 5-HT1B gene promoter by one of these amyloid 
peptides can be speculated. Another speculation is that the upregulation of 5-HT1B in APPswe 
cell could be a compensatory mechanism to the global, intra and extracellular, 5-HT deficit and 
increased 5-HT turnover in APPswe model prior to sertraline treatment[361] (Figure 4.1). 
4.2.2 Modulations of Extracellular 5-HT concentrations 
Measurement of Basal MAO-A activity and 5-HT metabolites in APPswe cells revealed 
lower extracellular 5-HT, higher 5-HIAA/5-HT index (Figure 4.6 C, D and E) and higher 
MAO-A activity (Figure 4.5). Of note, no difference in the basal levels of MAO-A gene 
expression between APPswe and control cells was found (Figure 4.5). The same pattern of 5-HT 
metabolites was observed after the measurement of intracellular levels from cells lysate (Figure 
4.6 F, G and H). 
To investigate the effect of modulating extracellular 5-HT levels on MAO-A and 5-HT-
turnover, we exposed both types of cells to a medium of 10 µM concentration of 5-HT for 30 
minutes. Significant increase of MAO-A gene expression, 5-HIAA production and 5-HIAA/5-
HT ratio, both extracellular and intracellular, were found in APPswe cells (Figure 4.7). No 
change of MAO-A activity following the 5-HT challenge in APPswe cells was observed. 
Our results are in agreement with previous reports that suggest low 5-HT and increased 
MAO activity in AD[41]. Despite the fact that these results are relevant to 5-HT deficit 
phenomena in AD, they are descriptive and they do not provide a mechanistic evidence of how 
APPswe overexpression alters MAO-A gene expression and 5-HIAA production. Similar to what 
have been mentioned in paper I , another limitation to paper II  is that the results are based on a 
single stable transfected cell line. Thus, it is not clear whether the data partially or totally depends 
on differences between cell lines or an APPswe overexpression. Moreover, there is lack of 
control that overexpresses the APP wild type (APPwt), which is considered the most appropriate 
control for APPswe cells and a better control than cells transfected with the empty vector alone. 
Additionally, the effect of sertraline on MAO-A gene expression is not included in the 
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experiments. MAO-B is also relevant to this area, and measurement of MAO-B was not 
performed in any of the sub-studies of this thesis. 
 
Figure 4.6 Basal levels of 5-HT1B gene expression and related serotonergic markers 
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Figure 4.7 Modulation of A. MAO activity B. gene expression and 5-HIAA productions after 5-
HT treatment both in cells medium C and intracellular D. 
 
We suggested that increased 5-HIAA productions and 5-HT turnover after elevating the 
extracellular 5-HT is due to the combined effect of higher basal line activity of MAO-A and the 
5-HT-induced stimulation of MAO-A synthesis at mRNA levels. Of note, SSRIs’ effects on 5-
HT pathway are not identical to the conditions where extracellular 5-HT is elevated rapidly. 
Intuitively, longer periods are needed for SSRIs to increase extracellular levels of 5-HT. 
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Therefore, addition of animal models to the study could have given more integrated and 
mechanistic information. Similarly, a proteomic confirmatory data, preferably at in vivo model 
level, is needed. Such data could help in understanding the reasons behind the lack of efficacy of 
SSRIs on treating depressive symptoms on AD[236].  
4.2.3 Modulations of 5-HT1B 
In control cells, the 5-HT1B antagonist SB224289 increased the gene expression of SERT. 
Higher SERT gene expression profiles are observed in the group subjected to the concomitant 
antagonist SB224289 and 5-HT treatment compared to any of them alone (Figure 4.3 C). 
Although it is not statistically significant, a similar response is also noted in APPswe cells. 
SB224289 has no effect in 5-HT or 5-HIAA in both cell types. These maybe due to the fact that 
the modification of SERT gene expression is more sensitive than modification in SERT function. 
SERT function modifications and subsequent behavioral response need longer time scales. 
Therefore, an animal model is needed to study this. We investigated 5-HT1B blockade effects on 
MAPK in APPswe. 5-HT1B was shown to activate MAPK signaling pathway[370]. As previously 
shown, the concentration we used of 5-HT (10 M) is the most optimal concentration to inhibit 
cAMP[370]. SB224289 inhibits MAPK in both APPswe and control cells (Figure 4.8). The 
combination of SB224289 and 5-HT activates p-70S6 kinase in APPswe. A trend of increase is 
also seen in Western blotting in two different p-S70S6 phosphorylations; phospho-p70S6 kinase 
(Thr389) and phospho-p70S6 kinase (Thr421-Ser424) (Figure 4.9). These conclusions should be 
taken with caution due to the difficulties in the quantifications of blots either in the Western 
blotting or MAPK protein arrays. 
S100A10, p11 is a relevant protein to 5-HT1B and depression[153]. Our results from 
Western blotting in APPswe indicate a reduction of p11 protein (Figure 4.1), while gene 
expression analysis indicates a marked increase in p11 mRNA compared to control cells (Figure 
4.3 E). This discrepancy between protein and gene expression in our results could be attributed 
to either methodological limitation of Western blotting or compensation in form of upregulation 
of the p11 gene expression due to reduced 5-HT1B protein levels. More proteomic methods 
such as ELISA or IHC are needed to confirm the p11 protein data. Another limitation is that 
these experiments were conducted with one experimental condition for SB224289, 5-HT or their 
combination. Moreover, interesting combinations such as SSRI and 5-HT1B antagonist were not 
tried. 
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Figure 4.8 MAPK phosphorylation after 5-HT and 5-HT1B blockade. 150 microgram of protein are 
incubated with each paper[352]. 
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Figure 4.9 MAPK, ERK and p70S6 assessed by Western blot after SB224289, 5-HT or both. 
V=vector or control cells and S=APPswe cells. C=Control cells treated with vehicle alone. S=5-HT, 
Ant=SB224289 and Sant=SB224289+ 5-HT  
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4.3 Platelets and serotonin metabolites in Alzheimer’s disease 
The platelets represent an interesting and accessible opportunity to study the serotonin 
system with relevance to brain. Of note, adjustment for density is important when measuring 5-
HT in AD, since both 5-HT levels and the species of platelets-derived amyloid are dependent on 
platelets density[275, 280]. Platelets with dual coating, coated with collagen and thrombin, have 
higher capacity in preserving the full length of APP compared to those with single coating[275]. 
We compared SCI group to AD group in a cohort obtained from memory clinic, Karolinska 
Hospital, Huddinge- Stockholm. As shown in Table 3.1, AD group is older and has lower 
MMSE scores. We investigated the association between platelets 5-HT and AD-CSF biomarker 
in both groups. Lower levels of 5-HT (p=0.016) and higher levels of 5-HIAA (p=0.044) in AD 
group are found when unadjusted non-parametric analysis was performed (Table 4.5 and Figure 
4.10). 
  
Table 4.5 Univariate and age-adjusted comparisons of serum serotonin level between the two study groups 
Variables SCI (n=20) 
AD 
(n=15) 
Univariate 
p-va lue# 
Adjusted 
Comparison 
Platelet Serotonin (5-HT) 
Crude level (nM/mL)-median (IQR) 
 
65.600 (117.575) 
 
1.000 (12.200) 
 
0.016 
B=-9.4§  
(95% CI: -126.2-107.3) 
(p-value=0.867) 
5-HT nM/ug of protein-median (IQR) 17.615 (37.165) 0.238 (1.630) 0.007  
Tertiles Category-n (%) 
1st tertile 
2nd tertile 
3rd tertile 
 
2 (10.0%) 
8 (40.0%) 
10 (50.0%) 
 
10 (66.7%) 
3 (20.0%) 
2 (13.3%) 
 
0.002 
 
OR=0.11*  
(95% CI: 0.01-0.82) 
(p-va lue=0.032) 
5-HT nM/platelet count-median (IQR) 0.342 (0.908) 0.008 (0.121) 0.017  
Tertiles Category-n (%) 
1st tertile 
2nd tertile 
3rd tertile 
 
3 (15.0%) 
6 (30.0%) 
11 (55.0%) 
 
8 (53.3%) 
5 (33.3%) 
2 (13.3%) 
 
0.008 
 
OR=0.18*  
(95% CI: 0.03-1.21) 
(p-value=0.077) 
Platelet 5-HIAA 
Crude level (nM/mL)-median (IQR) 
 
0.000 (0.710) 
 
0.560 (0.680) 
 
0.044 
B=0.44§  
(95% CI: -0.25-1.13) 
(p-value=0.195) 
5-HIAA nM/ug of protein-median (IQR) 0.000 (0.255) 0.193 (0.169) 0.178  
Tertiles Category-n (%) 
1st tertile 
2nd tertile 
3rd tertile 
 
11 (61.1%) 
2 (11.1%) 
5 (27.8%) 
 
3 (20.0%) 
6 (40.0%) 
6 (40.0%) 
 
 
0.093 
 
 
OR=10.55*  
(95% CI: 1.23-90.63) 
(p-va lue=0.032) 
5-HIAA nM/platelet count-median (IQR) 0.000 (0.005) 0.005 (0.007) 0.016  
Tertiles Category-n (%) 
1st tertile 
2nd tertile 
3rd tertile 
 
11 (61.1%) 
3 (16.7%) 
4 (22.2%) 
 
3 (20.0%) 
5 (33.3%) 
7 (46.7%) 
 
0.044 
 
OR=24.64*  
(95% CI: 2.55-238.48) 
(p-va lue=0.006) 
SCI: subjective cognitive impairment, AD: Alzheimer’s disease, IQR: interquartile range, OR: odds’ ratio, CI: confidence 
interval. 
Shapiro-Wilk test was used to check the normality of distribution of numeric variables in each study group. Multivariate 
linear and ordinal regression models were applied to adjust between-group comparisons for participants’ age, depression 
and p-selectin level. Statistical significant differences (two-tailed p-value<0.05) are bolded. 
# Mann-Whitney U-test            § Multivariate linear regression            * Multivariate ordinal logistic regression 
  76 
Due to the small sample size of the study, we divided each group (AD or SCI) into three 
equal tertiles according to 5-HT or 5-HIAA levels. Of note, 5-HT and 5-HIAA levels were 
adjusted to platelets count, protein concentrations, P-selectin levels and presence or absence of 
depression. The use of tertiles also was intended to lower the potential floor effect and compare 
the rank of each individual rather than the mean of the continuous values. Multivariate analyses 
indicate 66.7% of AD patient belong to the lowest first 5-HT tertile after protein adjustment 
(Table 4.5). In agreement with this result, 53.3% of AD patients are in the first tertile of 5-HT 
adjusted to platelets count. Interestingly, 5-HIAA showed reciprocal pattern of higher 5-HIAA in 
AD in both protein and platelets count adjusted analysis.  
We then studied the relationship between platelets-derived 5-HT or 5-HIAA and CSF-
derived AD biomarkers. The unadjusted Spearman correlation analysis showed negative 
correlation between 5-HT and T-tau/Aβ42 ratio in SCI, which indicate less AD-like CSF profile 
with the increase in platelets 5-HT content. However, these correlations were insignificant when 
the model was partial-age adjusted. As shown in Figure 4.10, 5-HT levels separate SCI group 
into two groups, one with high 5-HT levels (SCI-HS) and the other with relatively lower 5-HT 
(SCI-LS). SCI-LS group has higher CSF t-tau and t-tau/Aβ42 ratio compared to SCI-HS. This 
result indicates that SCI-LS has more AD-like CSF biomarker than SCI-HS (Figure 4.11). 
 
Figure 4.10 Crude, protein and platelets-adjusted 5-HT and 5-HIAA in SCI and AD. 
A B C
D E F
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Figure 4.11 Comparison of AD biomarkers in SCI groups according to their platelets 5-HT levels. 
HS=high serotonin, LS= low serotonin. 
 
In this study we used a single platelet fraction from SCI and AD group. Inclusion of one 
fraction could represent a limitation in this study, since alteration of platelets 5-HT in more than 
one platelets density fraction was reported[280]. The study did not include normal control or 
subject with mild cognitive impairment (MCI), which is an interesting intermediate group and 
could add more information about 5-HT levels in relation to AD severity stages. Measurement of 
platelets amyloid levels and 5-HT metabolites in CSF are also relevant to this area and can be 
done in future studies. The small sample size (15 AD subjects and 20 SCI) is a major limitation of 
this study, especially when they are later distributed into two groups based on 5-HT levels. 
Nonetheless, even with a total sample size of 35, our study showed significant differences 
between the two main groups and the subgroups. Another limitation in this study is the lack of 
platelets-derived MAO-B expression and activity data. 
Platelets lack MAOA-A, but express MAO-B and a possibility is that in the absence of 
MAO-A maybe MAO-B takes over the conversion of 5-HT to 5-HIAA. In addition, no inverse 
correlation between 5-HT and 5-HIAA, which implies that 5-HIAA inside the platelets is not a 
directly derived from platelets 5-HT. 
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5 CONCLUSIONS, LIMITATIONS AND FUTURE PERSPECTIVES 
5.1 Conclusions 
 
In this thesis, we investigated the relationship between 5-HT pathway and clinical and 
pathological changes associated in AD, using cell models, animal models, post-mortem brain 
tissue and platelets from living patients. Alterations of 5-HT system in AD and modulations of 
AD pathology by some 5-HT receptors such as 5-HT4 receptor were previously reported[311]. 
However, there is a gap of information regarding the role of 5-HT1B in both AD and other 
dementia subtypes. 
 
We show that 5-HT1B protein and gene expressions are reduced in APPswe mutation 
transfected SH-SY5Y neuroblastoma cell line. Consistent with these findings, lower hippocampal 
5-HT1B levels in the two-year-old female transgenic Tg2576 mice compared to controls were 
observed. However, in the human postmortem brain tissues, our results suggest an increase in 5-
HT1B levels in PFC area BA9. This variation in results between the two models maybe attributed 
to glial expression of 5-HT1B in response to neuronal loss in dementia. Another explanation is 
that increased expression 5-HT1B might be one of the molecular mechanisms of cognitive 
decline. Increased activity of 5-HT1B is associated with impaired working, reference and spatial 
memory tasks[76]. Consistent with this, our result indicates that in AD, PDD and combined 
dementia groups patients with high PFC-5-HT1B levels have more rapid decline of cognition. 
 
 The outcomes of pharmacological modulations of the serotonergic system differ between 
APPwe and wild-type cells. 5-HT1B receptor antagonist increased SERT gene-expression in 
control cells but not in the APPswe cells. Increased extracellular 5-HT levels lead to more 
MAOA-A gene expression and 5-HIAA productions in APPswe cells. Furthermore, sertraline 
increases the gene expression of 5-HT1B in APPswe cells. Our results suggest alterations of 
MAPK phosphorylations, particularly p70S6 and Erk in APPswe. However, no effects of 
sertraline or the 5-HT1B antagonist SB224289 were observed in intracellular or extracellular 5-
HT levels. These results deserve a detailed biochemical and behavioral follow up studies to 
understand the reported lack of SSRIs and serotonin and norepinephrine reuptake inhibitors 
(SNRIs) response in AD[236]. 
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We have studied differences in platelets serotonin between SCI and AD. Density of platelets, 
platelets count, and differences in protein concentrations were biochemical factors taken into 
consideration in our study. In medium-density platelets fractions, AD patients show significantly 
lower levels 5-HT and higher levels of 5-HIAA. In addition, SCI patients with lower platelets 5-
HT levels have higher CSF t-tau and t-tau/Aβ42 ratio. This reflects the association between AD-
like CSF biomarker pattern and platelets serotonin in early stages of AD.   
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5.2 Limitations 
In paper I : 
• Changes in 5-HT and 5-HIAA levels cannot be explained by alteration of 5-HT1B 
expression alone. For example, 5-HT1A is another autoregulatory receptor for 5-HT. The 
study lacks the correlation between 5-HT1B expression and 5-HT metabolites level, which 
would provide an evidence of the relationship. 
• The study consists of only one genetic model for familial AD, APPswe mutation. Inclusion 
of other genetic models such as presnilin-1(PSEN1) and presiniln-2 (PSEN2) mutations 
would give more information in this area. 
• We did not show the effect of APPwt on 5-HT metabolites. However, our preliminary 
results have shown no difference in 5-HT1B levels between control cells and cells that 
overexpress the non-mutated wild type of APP (APPwt cells). 
• The discrepancy between proteomic and gene expression data of p11 could be due to 
inherited limitations in the Western blot. The study does not provide confiramtory 
proteomic methods such as ELISA or immunofluorence to support Western blotting 
results. 
• Results from mice hippocampal 5-HT markers lack information from 9 months and 12 
months age-groups in the wild type mice. Moreover, mice included in this study were only 
female and that represents a limitation in generalizing the serotonergic results. This is 
because of logical metabolic and neuroendocrine differences between sex groups such as 
influence of sex hormone in 5-HT pathway. Although data from 5-HT1B hippocampal 
expression is relevant to AD, inclusion of other areas such as neocortex would have shown 
the pattern of 5-HT1B expression in mice brain. Finally, the levels of 5-HT metabolites in 
mice hippocamus are not measured. 
• Only one cell line was used in this study. 
In paper II : 
• The results are descriptive, i.e., there are no mechanistic insight on how overexpression of 
APPswe alters 5-HT pathway. 
• Similar to paper I, APPwt cells are not included in this study 
• Studies conducted with transgenic mice should be performed in order to demonstrate that 
all AD models have similar results. 
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• We used one time and concentration point for each experimental condition. Inculsion of 
different points would explain the time and dose-related effect of experimental conditions 
in 5-HT pathway modulations. Furthermore, it would be interesting if the combined effect 
of sertraline and 5-HT1B antagonist was tested. 
In Paper III : 
• The study represents a comparsion between only two groups AD and SCI. Addition of 
healthy controls and patients with MCI would have added better insight about platelets 5-
HT metabolites in different dementia stages. 
• The study has a relatively small sample size which makes adjustment to different clinical 
variation difficult. 
• No correlation is provided between CSF and platelet 5-HT metabolites was shown.  
• The analytic assays seem to display a "floor effect" with a significant number of samples 
scoring very close to zero. However, we checked the crude values and found that in 6 cases, 
17.1%, the level of 5-HT is quite low with a value of 0 for at least three decimals. Of these, 
5 were in the AD group, which thus lends support to the finding of low levels in AD. The 
major contribution to this variation and the low 5-HT levels are related to the additional 
purification step, i.e., sorting cells in a gradient and selecting the right fraction. This makes 
the whole assay more vulnerable than a typical measurement of 5-HT levels in plasma-free 
platelet samples. In addition, we decided to also transform continuous values into tertiles to 
lower the potential floor effect and compare the rank of each individual rather than the 
mean of crude continuous values. However, consistent results after different type of 
adjustment lend support to our conclusions. 
• Both study groups differ in age and depression frequency. After adjustment to these 
variables, no association between 5-HT or 5-HIAA levels and CSF biomarkers. We believe 
this is mostly due to the rather small sample size. However, in the analyses using tertiles the 
association remained statistically significant even after adjustment. 
In paper IV 
• Results in this study are not adjusted to releveant factors to 5-HT system such as 
depression scales and serotonin-modulating drug intake. 
• There is no inclusion of other brain regions relevent to memory functions such as 
hippocampus. 
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• There is a need for a confirmatory proteomic method such as Western blotting or IHC. 
This was done for both pathological and synaptic markers but not for 5-HT1B. 
• Similar to paper III , the sample size of individual dementia sub-group is small, added to 
the missing information about particular varibles in subjects (range from 0 to 7), these 
factors affect the power of the study. 
• There is a lack in information about baseline MMSE scores in the participants. Baseline 
MMSE might influence both the last MMSE prior to death and the annual rate of MMSE 
decline, which further affects the results we obtained in Table 4.3 and Table 4.4. 
5.3 Future perspectives 
More work is needed in order to understand how the 5-HT system is altered in 
neurodegenerative diseases, their clinical and therapeutic relevance. So, we suggest the following: 
• Mechanistic studies elaborating in detailed interactions between pathological changes 
including amyloid and tau pathologies and alteration in the 5-HT pathway are needed. For 
example, computational chemistry analysis for structural interactions between amyloid 
peptides and MAO-A would improve our understanding for mechnasim of increased 5-HT 
degredation in in vitro AD models. 
• Using the new neuroimaging tools such as PET  in human and novel ligands binding to 
serotonergic receptors in animal models to investigate expression of 5-HT1B and other 
receptors in AD and correlate the findings to clinical and biomarkers information. 
• Analysis of S100A10 (p11) in AD brain samples would also expand our understanding 
about the clinical relevance of 5-HT1B and 5-HT4, since the protein is modulating these 
receptors and has significant implication in depression and antidepressant effect. 
• The bidirectional relationship between 5-HT pathways and AD neuropathology should be 
explored in details, since 5-HT receptors influence the processing of amyloid precursor 
protein and amyloid peptides, and vice versa, amyloid neurotoxicity affects the brain 
expression of 5-HT pathway molecules. 
• Finally, and most importantly, improved understanding of 5-HT1B and other 5-HT 
molecules can lead to better treatment of both cognitive and affective changes assocaited 
with AD and other neurodegenerative diseases.  
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